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Alcohol consumption and smoking are
undisputedly the main risk factors for
upper digestive tract cancers in humans.
Billions of people worldwide engage in
these behaviours, thus creating disease
burden. Strong experimental and human
genetic linkage data suggest that
acetaldehyde is one of the major factors
behind the carcinogenic effect of alcohol
drinking. In the digestive tract,
acetaldehyde is mainly formed by
microbial metabolism of ethanol.
Acetaldehyde is also a major constituent
of tobacco smoke. Thus, acetaldehyde
from both of these sources may have an
interacting carcinogenic effect in the
human upper digestive tract. Earlier
experimental studies have shown that the
amino acid cysteine has the ability to bind
reactive acetaldehyde. The local use of
cysteine might therefore be able to prevent
the harmful effects of acetaldehyde.
AIMS
The first aim of this thesis was to elucidate
the capacity of microbes to produce
acetaldehyde from ethanol in different
atmospheric conditions prevailing in the
human digestive tract.
The second aim was to investigate
acetaldehyde production and exposure in
the human mouth resulting from alcohol
ingestion and tobacco smoking in vivo.
Thirdly, specific L-cysteine products were
prepared to examine their efficacy in the
binding of salivary acetaldehyde in order
to reduce the exposure of the upper
digestive tract to acetaldehyde.
METHODS
Firstly, the acetaldehyde production and
ethanol fermentation of Escherichia coli –
an important member of the human
microbiota – was measured in vitro in
anaerobic, aerobic and microaerobic
conditions.
In other studies, acetaldehyde was
measured in the saliva of human
volunteers in vivo during alcohol
metabolism, during tobacco smoking and
during the combined use of alcohol and
tobacco. The ability of L-cysteine to
eliminate acetaldehyde during alcohol
metabolism was also measured by using a
specifically developed slow releasing
buccal tablet. In addition, the ability of L-
cysteine to eliminate acetaldehyde
dissolved in saliva from tobacco smoke
was examined by using a L-cysteine-
containing tablet that was sucked during
smoking.
RESULTS AND CONCLUSIONS
In vitro results with E. coli demonstrate
that ADH activity-possessing bacteria
representing the normal human microbiota
can be one regulatory factor in
acetaldehyde production, leading to
marked formation of carcinogenic
acetaldehyde from ethanol, especially
under aerobic or microaerobic conditions.
Acetaldehyde produced in the oral cavity
during ethanol challenge was significantly
decreased by a buccal L-cysteine -
releasing tablet. L-cysteine efficiently
bound reactive acetaldehyde by forming a
stable thiazolidine compound, thus
preventing the reactivity of acetaldehyde
against mucosal cells. Furthermore,
9
smokers were established to have
significantly increased acetaldehyde
exposure during ethanol metabolism even
when not smoking. However,
acetaldehyde exposure is dramatically
further increased during active tobacco
smoking. Thus, the elevated aerodigestive
tract cancer risk observed in smokers may
be the result of the acetaldehyde exposure
from tobacco smoke. Moreover, the
dramatically increased exposure to
carcinogenic acetaldehyde caused by
simultaneous smoking and drinking may
explain the synergistic and multiplicative
effect of alcohol consumption and tobacco
smoking on upper digestive tract
carcinogenesis.
The last study of this thesis shows that
smoking-derived acetaldehyde can be
totally removed by using a tablet
containing L-cysteine. Hence, a cysteine
tablet sucked during each smoking period
could be used to eliminate acetaldehyde
exposure, thus potentially preventing
upper digestive tract cancers in smokers.
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INTRODUCTION
A large proportion of upper digestive tract
cancers are attributable to alcohol
consumption and smoking. These risk
factors account for over 75% of all cases in
developed countries (Franceschi et al., 1990;
La Vecchia et al., 2004). Moreover,
evidence indicates that the combined use of
alcohol and tobacco increases the risk of
these cancers multiplicatively, i.e. each
factor multiplies the effect of the other.
Compared with never-smokers and alcohol
abstainers, the relative risk of upper
digestive tract cancers may be more than
100-fold higher in heavy smokers and heavy
drinkers. Already the consumption of 20 -
30 g (two drinks) of alcohol per day
markedly increases the risk of upper
digestive tract cancer (Bagnardi et al.,
2001b). Thus, the consumption levels and
trends of use of alcohol and tobacco have a
major influence on the total incidence and
mortality rates of oral, pharyngeal, laryngeal
and oesophageal cancers.
Many possible mechanisms by which
alcohol causes cancer exist. However, cell
culture and animal studies strongly suggest
that acetaldehyde is the main factor
responsible for the carcinogenic effect of
alcohol, whereas ethanol per se is not a
carcinogen (IARC, 1988; IARC, 1999).
Very recent molecular studies have shown
that acetaldehyde induces carcinogenic
changes in concentrations that have been
measured in human saliva after a moderate
dose of alcohol (Brooks and Theruvathu,
2005).
In addition to experimental studies,
polymorphism of ethanol-, and
acetaldehyde- metabolizing genes – alcohol
dehydrogenase (ADH) and aldehyde
dehydrogenase (ALDH) – can be used to
assess the association between acetaldehyde
and cancer in humans. The risk of upper
digestive tract cancers is markedly increased
in individuals with impaired acetaldehyde
removal due to a mutation in the ALDH2
gene (Yokoyama et al., 1998). The
mutation, which is common in Asians,
results in elevated levels of acetaldehyde in
saliva after alcohol challenge, thus
subjecting these individuals to higher local
acetaldehyde exposure (Väkeväinen et al.,
2000) and greater risk of upper digestive
tract cancers than individuals with a normal
ALDH2 enzyme. Caucasian heavy drinkers
and alcoholics with high-activity ADH and
enhanced local acetaldehyde production in
the mouth presumably also have an
increased risk of upper aerodigestive tract
cancers (Homann et al., 2005; Visapää et al.,
2004).
Acetaldehyde is known to be locally formed
in the upper digestive tract, mainly by
microbes representing normal oral flora
(Jokelainen et al., 1996a). Salivary glands
and mucosal cells may also act as minor
contributors to the acetaldehyde
concentration present in saliva during
ethanol metabolism (Visapää et al., 2002;
Väkeväinen et al., 2000). Microbial
acetaldehyde production is strongly
influenced by individual factors and
differences in oral flora (Homann et al.,
2000). Thus, elucidation of genetic and
environmental factors contributing to the
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local concentration of carcinogenic
acetaldehyde in saliva is essential when
considering individual risk and possible
prevention of upper digestive tract cancers.
Acetaldehyde is also one of the major
components of tobacco smoke (Hoffmann
and Hoffmann, 1997). Although tobacco
smoke contains several substances classified
as carcinogens, their individual roles in vivo
remain obscure. Thus, elucidation of
tobacco-derived acetaldehyde as a possible
factor underlying aerodigestive tract cancers
is also needed. The pathogenesis behind the
multiplicative carcinogenic potential
associated with the combined use of alcohol
and tobacco has thus far been unknown.
Because acetaldehyde has multiple cancer-
promoting mechanisms, this thesis presents
a new hypothesis that the combined
exposure to acetaldehyde derived from
tobacco smoke and microbial alcohol
metabolism explains the multiplicative risk
effect.
Thiols such as L-cysteine, have been known
for decades to bind acetaldehyde. By
eliminating toxic acetaldehyde, L-cysteine
may protect experimental animals from its
lethal effects (Sprince et al., 1975).
However, numerous studies have to date
failed to show any chemopreventive effect
of L-cysteine in vivo (Meister, 1989). As
acetaldehyde is formed in saliva during
alcohol metabolism and also dissolves in
saliva during tobacco smoking, the second
goal of this thesis was to find a novel
method – by using L-cysteine – to reduce
the acetaldehyde concentration in saliva and
thereby also the local exposure of the upper
digestive tract mucosa to carcinogenic
acetaldehyde.
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REVIEW OF THE LITERATURE
A systematic review was undertaken of all
published data on deleterious impact of
alcohol consumption on the human upper
digestive tract. Literature about the
combined effects of alcohol and tobacco
smoking was also systematically reviewed.
This was followed by a literature review of
the data concerning acetaldehyde as a
carcinogenic factor related to alcohol
consumption and smoking. Finally, different
regulatory factors influencing local in vivo
acetaldehyde concentration in the upper
digestive tract were analysed.
Searches were limited to MEDLINE (Ovid
medline (R)) from 1966 to 2005 and the
English language, and recently updated to
include possible new studies on the topic. A
PubMed search was also conducted when
indicated. These searches were
complemented with manual searches of
references in other published articles when
necessary. Search terms (mapped to Medical
Subject Headings of the database) used in
combination are defined at the beginning of
each section and the number of total
identified publications [number in
parentheses] is also given. In some cases,
the search term was limited to certain
subheadings to restrict the focus of the
search [indicated in parentheses].
*, indicates that the search was run for the
selected term and only those results were
retrieved in which that term represents the
central concept of the records.
Exp, indicates that the search was run for
the selected term in combination with all of
its conceptually narrower terms from the
tree display.
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1 EPIDEMIOLOGY OF UPPER DIGESTIVE TRACT CANCERS
1.1 Alcohol and upper digestive tract
cancers
Search terms:
*Alcohol drinking AND neoplasms
(aetiology, epidemiology) [101]
OR
*Alcohol drinking AND exp mouth
neoplasms (aetiology, epidemiology) [92]
OR
*Alcohol drinking AND exp pharyngeal
neoplasms (aetiology, epidemiology) [95]
OR
*Alcohol drinking AND laryngeal
neoplasms (aetiology, epidemiology) [75]
OR
*Alcohol drinking AND oesophageal
neoplasms (aetiology, epidemiology) [109]
OR
*Alcohol drinking AND stomach neoplasms
(aetiology, epidemiology) [40]
To cover all meta-analyses, a PubMed
search was also performed with the terms
meta-analysis AND cancer AND alcohol
drinking [50].
As a result, 381 publications were reviewed
by abstract and were included in the review
if the following criteria were met: meta-
analysis, cohort or case-control study
published as an original article; findings
expressed as odds ratios (OR) or relative
risks (RR).
Altogether 141 publications met the
inclusion criteria; 118 were case-control
studies, 16 cohort studies and seven meta-
analyses (one was a double publication;
furthermore, four additional meta-analyses
were found but RRs
or ORs were not expressed). Seven of the
141 studies evaluated the association
between alcohol consumption and
precancerous lesions (e.g. leukoplakia,
erytroplakia) instead of cancer. The first
meta-analysis (Holman et al., 1996) (16
cohorts and 1 084 733 subjects) reviews the
data published in Medline from 1980 to
1994 and covers oropharyngeal, laryngeal
and oesophageal but not oral cancer risks.
The two most recent meta-analyses review
the cancer data to the year 2000 (Bagnardi et
al., 2001b) and 2001 (Zeka et al., 2003). In
Bagnardi’s meta-analysis (235 studies and
117 471 subjects), epidemiological literature
on the association between alcohol
consumption and the risk of 18 neoplasms,
including oral cavity, pharyngeal, laryngeal,
oesophageal and stomach cancers was
evaluated. In Zeka’s meta-analysis (15
studies and 9 508 subjects), epidemiological
evidence on associations between alcohol
and tobacco consumption and cancers of the
oropharynx, pharynx, larynx and
oesophagus was reviewed. Two of the seven
meta-analyses explored the relationship of
alcohol consumption with several alcohol-
related conditions (Corrao et al., 1999;
Rehm et al., 2003). Corrao’s meta-analysis
(200 studies and 97 351 subjects) covers
malignant neoplasms of the lip, oral cavity
and pharynx combined, in addition to
oesophageal neoplasms. Rehm’s publication
(a review of nine meta-analyses) comprises
combined oral and oropharyngeal cancers
and oesophageal cancer. The very latest
meta-analysis by Altieri (20 studies and 42
822 subjects) covers only the association of
alcohol consumption and risk of laryngeal
cancer based on studies published after 1988
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(Altieri et al., 2005). The seventh meta-
analysis, covering alcohol consumption and
cancers of the digestive tract and larynx,
was manually found from references (Doll
et al., 1999) (18 cohort studies with over
695 000 subjects and 37 case-control
studies). To avoid an enormous number of
references, this systematic literature review
includes only these meta-analyses
complemented with more recent studies
after 2001. Thus, 17 case-control studies and
six meta-analyses were included. Four of
these 17 case-control studies were based on
the same study population.
1.1.1 Mouth and pharynx
Strong epidemiological evidence indicates
that alcohol consumption increases the risk
of cancers of oral cavity and pharynx. The
risks are by and large due to total ethanol
intake, increasing with the amount of
ethanol consumed. All studies confirmed the
carcinogenic effect of ethanol on oral and
pharyngeal cancers. For oral and pharyngeal
cancers (and also for other upper digestive
tract cancers), significantly increased risks
have been found for fairly quite low doses
of ingested alcohol, i.e. 25 g/day which
corresponds to approximately two drinks per
day. Daily consumption of 0-40 g of ethanol
(or 0-4 drinks) increases the relative risk
(RR) for oropharyngeal cancer to 1.5-2.06
(Bagnardi et al., 2001b; Zeka et al., 2003;
Znaor et al., 2003). The RR for oral cavity
and pharyngeal cancers increases with the
amount of alcohol consumed. The RR for
oral or pharyngeal cancer with daily intake
of 50 g and 100 g of alcohol is 2.85 and
6.01, respectively (Bagnardi et al., 2001b).
According to Corrao’s meta-analysis, the
RR for malignancy of the lip, oral cavity and
pharynx reaches 10.7 for a daily dose of 100
g of ethanol (Corrao et al., 1999). Moreover,
four or more drinks daily results in 7.2-fold
RR for oropharyngeal cancer (Zeka et al.,
2003). These conclusions are confirmed by
the third meta-analysis by Holman et al., in
which the RR for oropharyngeal cancer was
5.39 for persons ingesting five or more
drinks per day (Holman et al., 1996).
Thus, there is a unanimous, independent
causal effect of alcohol on oral and
pharyngeal cancers. However, some debate
exists about the threshold level.  The
threshold may vary from 20 to <50 g of
ethanol per day for cancers of the pharynx
and larynx (Polesel et al., 2005).
Furthermore, data are insufficient to
conclude that the carcinogenic effect is
dependent on a specific type of alcoholic
beverage. More important appears to be the
total alcohol consumption. The most
frequently consumed beverage in each
region appears to be the one with the highest
association (Bagnardi et al., 2001b).
1.1.2 Larynx
Strong evidence suggests that alcohol
drinking is causally related also to laryngeal
cancer. The RR seems however, to be
somewhat lower than that for oropharyngeal
cancer. There is some inconsistency in the
cancer risks based on the anatomical site of
larynx, which may be due to a classification
bias.  Tobacco smoking may have a more
striking role in laryngeal cancers than
alcohol consumption, since results from a
case-control study in non-smoking drinkers
(40 cases/160 controls) and non-drinking
tobacco smokers (68 cases/161 controls)
showed no increased risk for laryngeal
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cancer in moderate drinkers. However, the
risk was increased with elevated alcohol
consumption (Bosetti et al., 2002). An
estimated 90% of laryngeal cancers are
attributable to tobacco, while alcohol
explains approximately 58% of cases
(Altieri et al., 2002). Nevertheless, the meta-
analysis of laryngeal cancer clearly shows
that alcohol consumption is strongly
associated with an increased risk of
laryngeal cancer. The RR for the highest
levels of alcohol consumption ranged
between 2 and 10, and were 1.07-1.83 for 0-
25 g/day, 1.94-4.5 for 50 g/day and 3.95-
4.93 for 100 g/day. Some consumption
figures are rounded since alcohol
consumption levels in different studies are
expressed either as drinks/day or g/day. In
general, one drink is estimated to contain 10
g of pure ethanol (Altieri et al., 2005;
Bagnardi et al., 2001b; Holman et al., 1996;
Zeka et al., 2003).
The cancer risk may also differ by laryngeal
anatomical subsites, the supraglottis being
more closely related to alcohol consumption
than the glottis/subglottis (De Stefani et al.,
2004). This is logical as the glottis and
subglottis are more exposed to inhaled
agents. Therefore the cancer-related RR for
supraglottic cancers (OR 3.9 95% CI 2.3-
6.7) is higher than that of glottic carcinomas
(OR 2.1, 95% CI 1.2-3.7) (481 cases) (De
Stefani et al., 2004). There is no indication
that the carcinogenic effect is dependent on
the type of alcoholic beverage (Altieri et al.,
2005).
1.1.3 Oesophagus
There is a strong, direct risk for cancer of
the oesophagus related to alcohol
consumption. The RR for oesophageal
cancer associated with alcohol intake are
similar in all reviewed meta-analyses.
Moreover, a clear dose-response relationship
exists with alcohol consumption. According
to meta-analyses, for the lowest level of
alcohol consumption, i.e. 0-25… 40 g of
ethanol daily, the RR for oesophageal cancer
is between 1.4 and 2.2 (Corrao et al., 1999;
Zeka et al., 2003). For the highest level of
alcohol consumption, i.e. 100 g/day, the
mean RR for oesophageal cancer varies
from 4.23 to 10.7 (Bagnardi et al., 2001b;
Corrao et al., 1999). For oesophageal cancer
risk, the effect of gender in modifying the
risk effect has been reported. Women have a
slightly but significantly higher risk for
oesophageal cancer than men (Bagnardi et
al., 2001b).
According to case-control studies, the ORs
for oesophageal cancer for the highest
alcohol consumption level (>50 ml/day and
>40 g/day) are 3.6 in India (Znaor et al.,
2003) (566 cases/1711 controls) and 19.5 in
Taiwan (Lee et al., 2005a) (531 cases/818
controls). This large difference can perhaps
be explained by genetic differences in
alcohol and acetaldehyde metabolism
related to ethnicity. Large differences are
also present in the incidence of oesophageal
cancer in Europe. This may be due to the
types of alcoholic beverages consumed. The
highest incidence rate of oesophageal cancer
has been reported in Calvados, France
(26.5/100 000 vs. 3-12/100 000 in other
areas in the Europe). The specific
aetiological cause in this case has been
speculated to be the calvados-spirit (Boeing




Only one meta-analysis reports the RR for
alcohol-related stomach cancer (Bagnardi et
al., 2001b). According to this, a small but
significant and steadily rising stomach
cancer risk is present with increasing
alcohol consumption, the RR being 1.05,
1.15 and 1.32 for 25 g, 50 g and 100 g of
daily alcohol, respectively. On the other
hand, Doll’s meta-analysis including 18
cohort and 37 case-control studies
concluded that there is insufficient evidence
that alcohol is involved in the aetiology of
stomach cancer (Doll et al., 1999).  The
majority of reviewed case-control studies
concerning stomach cancer have found no
statistically significant association between
alcohol consumption and gastric cancer
(Barstad et al., 2005; Engel et al., 2003;
Hamada et al., 2002; Kelley and Duggan,
2003; Key et al., 2004; Lindblad et al.,
2005; Nishimoto et al., 2002; Sasazuki et al.,
2002), although one study suggested a
positive but not significant trend for cancer
of the gastric cardia (Rao et al., 2002). The
RR for gastric cardia cancer for those who
consumed alcohol >322.5 g alcohol/week
was 3.0 (range 0.8-11.1). A significant J- or
U-shaped effect of drinking on the risk for
stomach cancer was found in a Japanese
study (787 cases/1007 controls) in which
adjustment was made for the Helicobacter
pylori status (Kikuchi et al., 2002).
This discrepancy in results with regard to
stomach cancer and alcohol consumption is
also noted in the IARC summary (not
included in this review because it was from
year 1988) which evaluated 13 cohort
studies and 12 case-control studies (IARC,
1988). It concluded that little aggregate data
exist to suggest a causal role for drinking of
alcoholic beverages in stomach cancer.
Furthermore, if alcohol has an aetiological
role, it is minor and unproven.
Epidemiological studies show that incidence
of gastric cancer has declined sharply in
previous decades. On the other hand, in
developed countries there has been a rapid
increase in the incidence of gastric cancer
localized to the cardia (Kelley and Duggan,
2003). The rapid increase in the incidence of
oesophageal and gastric carcinomas has
been suggested to result from increases in
the prevalence of several modifiable risk
factors, including alcohol consumption, diet,
overweight, gastrooesophageal reflux and
definitely tobacco smoking. The well-
recognized risk factor for H. pylori for
stomach cancers would not explain this
phenomenon since it is probably a minor
cause in developed countries and mainly a
risk factor for non-cardia gastric cancer
(Engel et al., 2003).
In conclusion, there is an undisputed, level
A grade of evidence (from large systematic
reviews, meta-analyses and cohort studies)
of a positive association between alcohol
consumption and cancers of the mouth,
pharynx, larynx and oesophagus.
Furthermore, this is a dose-response
relationship. In the case of stomach cancer,
the data are inconsistent and further
epidemiological studies with higher alcohol
consumption levels are warranted. Thus, this
review confirms by and large the
conclusions of the systematic review of the
IARC from 1988. However, possible biases
must be taken into account, which may
explain certain discrepancies. Factors such
as incidence of cancer, food intake, lifestyle
and ethnicity (with regard to different
genetic differences in ethanol and/or
acetaldehyde metabolism) of the study
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population might influence results,
especially those related to oesophageal and
stomach cancer risk and alcohol
consumption. The dose-response effect of
alcohol on upper digestive tract cancers
without specific adjustments for ethnicity or
genetic differences is summarized in Figure
1.
Figure 1. Effect of alcohol consumption on oropharyngeal, laryngeal and oesophageal cancer risks




























1.2 Synergistic effect of alcohol and
tobacco on upper digestive tract cancers
Search terms:
Alcohol drinking AND * smoking
AND













To cover all meta-analyses and the most
recent studies, a search was also performed
in PubMed (restricted to the years 2001-
2005) with the following terms:
- Alcohol drinking AND smoking AND
cancer AND meta-analysis [11]
- Alcohol drinking AND smoking AND
cancer AND combined [55].
As a result, 305 publications were reviewed
by abstract and were included in the review
if the following criteria were met: meta-
analysis, cohort or case-control study
published as an original article, findings
expressed as ORs or RRs and the combined
effect of alcohol drinking and smoking
specifically reported.
Altogether 85 publications met the inclusion
criteria. Of the included studies, 78 were
case-control studies, four cohort studies and
three meta-analyses. These meta-analyses
from Bagnardi, Zeka and Altieri cover the
published literature for different databases
(Medline, Current contents, etc) to the year
2000 (Bagnardi et al., 2001a), 2001 (Zeka et
al., 2003) and  2005 (Altieri et al., 2005),
respectively. More detailed descriptions of
these publications are given in the preceding
section.
The IARC has published an up-to-date
monograph of the IARC working group
meeting on June 2002 concerning tobacco
smoking (IARC, 2004). An extensive
summary is included in the IARC
monograph covering all relevant
publications (to 2001) concerning the
combined effects of alcohol drinking and
tobacco smoking on cancers of the upper
aerodigestive tract (IARC, 2004).
To avoid an excessive number of references,
only the three meta-analyses, IARC
monograph and publications from the year
2002 were included in this review. Thus,
three meta-analyses, two cohort studies and
14 case-control studies were reviewed. Both
cohort studies are Japanese, one reporting
the risk effect of smoking and alcohol
drinking on oesophageal cancer (Sakata et
al., 2005) and the other on stomach cancer
(Kikuchi et al., 2002).
Alcohol and tobacco are the best-recognized
and unquestioned risk factors in developed
countries for oral, pharyngeal, laryngeal and
oesophageal cancers. Alcohol and tobacco
enhance each other’s effects on the risk for
the above-mentioned cancers. It has been
estimated that due to this synergism over 75
% of cancers of the upper digestive tract are
attributable to alcohol and tobacco, and
therefore, avoiding tobacco and alcohol
could prevent the majority of cases
(Bagnardi et al., 2001a). Despite smoking
and drinking being known risk factors,
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separating their independent effects remains
difficult since heavy drinkers tend to be
heavy smokers, and vice versa.
Furthermore, studies often include too few
cases who neither smoke nor drink (Altieri
et al., 2002). Nevertheless, according to
most of the epidemiological studies, the
joint effect of alcohol consumption and
tobacco smoking on cancer risks of the oral
cavity, pharynx and oesophagus follow the
multiplicative model, i.e. the combined
effect of both of these agents is greater than
simply adding the effects together.
1.2.1 Mouth and pharynx
The RR for cancers of the oral cavity and
pharynx, including the synergistic effect of
alcohol and smoking for the highest
exposure levels of both risk factors, ranges
in meta-analyses from 21.2 (Zeka et al.,
2003) to 51 (Castellsague et al., 2004). The
latest IARC review reports the respective
RRs to range from 5 to 77.3. The huge
variation in risk is due to the different
consumption levels reported in the studies.
The highest level of tobacco use reported to
range from >10 g (of tobacco)/week to >40
cigarettes/day (a cigarette weighs
approximately 1 g with the tobacco content
varying between 65 % and 100 %,
depending on the type of cigarette) and
alcohol consumption from >20 g/day to 85
drinks/week (one drink is about 10 g of
ethanol). There are also discrepancies
between some studies, e.g. the RR for oral
cancer in non-drinking heavy smokers may
be 1 or less which is the opposite reported in
the majority of the studies considering
cancer risks at the same anatomical site
(IARC, 2004). The independent effect (RR)
of smoking on non-drinking subjects for oral
cavity or pharyngeal cancer ranges from
1.85 to 13.6 (Castellsague et al., 2004;
Huang et al., 2003).  All studies confirm the
synergistic effect of alcohol use and
smoking on oral and pharyngeal cancer risk
(Bagnardi et al., 2001a; Castellsague et al.,
2004; Huang et al., 2003; IARC, 2004;
Lissowska et al., 2003; Zeka et al., 2003).
1.2.2 Larynx
Most of the case-control studies on
laryngeal cancer provide strong evidence for
the synergistic effect of alcohol
consumption and smoking (IARC, 2004).
However, the meta-analysis of Bagnardi et
al., suggests that the combined and
independent effects of alcohol and tobacco
smoking on laryngeal cancer are somewhat
inconsistent compared with oropharyngeal
and oesophageal cancers (Bagnardi et al.,
2001b). This is most probably due to the
glottic and subglottic regions of the larynx
anatomically being exposed to inhaled
agents. Thus, smoking has a more
pronounced effect on the cancer risk in some
areas. The independent effect on the OR for
cancer at the highest level of smoking alone
ranged in the reviewed publications from 7.7
to 18.9 (Talamini et al., 2002; Zeka et al.,
2003). When alcohol consumption (highest
level) was combined with smoking, the RR
increased multiplicatively. A case-control
study of women (68 cases/340 controls)
reports a very high OR for laryngeal cancer
risk. Subjects who smoked >15
cigarettes/day and consumed > 3 alcoholic
drinks/day had an OR of 317 (Gallus et al.,
2003). The highest RR for combined action
of alcohol and tobacco is reported in
Guenel’s study (411 cases/4135 controls).
The consumption of >160 g/day of alcohol
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combined with the highest smoking category
(>30 g/day) yields an RR for glottic and
supraglottic cancers of 289 and 1094,
respectively (IARC, 2004). These very high
RRs might be due to too few cases and/or
controls in these studies. However, these
results are consistent with the multiplicative
risk model of the combined effect of alcohol
and tobacco smoking on laryngeal cancer. In
Altieri’s meta-analysis including 20 studies,
the risk estimate for laryngeal cancer for the
highest level of consumption for both
factors as compared with the lowest one
were from 8.0 to over 100, and a
multiplicative risk model was indicated
(Altieri et al., 2005). Also the meta-analysis
of Zeka et al., suggests a multiplicative
nature – at least more than additive – of the
joint exposure to alcohol and tobacco (Zeka
et al., 2003). Case-control studies from India
and France conclude that the joint effects of
smoking and drinking are greater than
additive (Menvielle et al., 2004; Znaor et al.,
2003). In the review of IARC, only one
study from the year 1992 (Zheng et al.,
1992) reported evidence inconsistent with
the synergistic effect of alcohol and
smoking.
1.2.3 Oesophagus
Both  meta-analyses (Bagnardi et al., 2001b;
Zeka et al., 2003), and three of the four
case-control studies (513 cases/818
controls); (Lee et al., 2005b), (805
cases/3461 controls); (Garavello et al.,
2005), (1248cases/1248 controls); (Ke et al.,
2003) and the cohort study (42 578
subjects); (Sakata et al., 2005) concluded
that a synergistic interaction exists between
alcohol consumption and smoking with
regard to oesophageal cancer risk. One case-
control study from Taiwan (309 subjects)
found no association between alcohol
consumption and oesophageal cancer risk
(Wu et al., 2003). This conclusion was,
however, based on subjects being defined as
alcoholics with alcohol consumption as low
as one dose per week, which is far from
abuse. The seven case-control studies and
one cohort study included in the IARC
review support the joint effect of smoking
and alcohol use and conclude that the risk
seems to be greater than additive (IARC,
2004). In addition, the first analysis of the
EPIC study with 412 000 cases of
oesophageal cancer confirms that there is a
multiplicative effect on cancer risk with
concomitant exposure to heavy drinking and
smoking (Boeing and EPIC Working Group
on Dietary Patterns., 2002) (not included in
this review because of unfinished analysis).
Based on the reviewed studies, the highest
combined risks for the highest levels of
alcohol use and tobacco smoking range from
4.3 (Ke et al., 2003) to 149 (IARC, 2004).
The IARC monograph also reports findings
from nine case-control studies and one
cohort study on cancers of the “mixed upper
aerodigestive tract”, including subjects with
squamous cell carcinomas on a non-specific
site in the head and neck regions. These
studies provide strong evidence for the
synergistic action of smoking and alcohol
consumption on cancer risk (IARC, 2004).
The results regarding the synergistic and
multiplicative effect of smoking and alcohol
on mixed upper aerodigestive tract cancers
are summarized in the Figure 2, which
includes six case-control studies reporting at
least three smoking categories and three
alcohol consumption categories in non-
Oriental populations (Andre et al., 1995;
Baron et al., 1993; Franceschi et al., 1990;
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Kabat et al., 1994; Maier et al., 1992;
Mashberg et al., 1993).
1.2.4 Stomach
No consistent data are available about the
independent effect of alcohol consumption
on gastric cancer. Hence, one cannot
conclude anything about the synergism of
tobacco and alcohol on stomach cancer risk.
Furthermore, none of the reviewed
publications report a possible synergistic or
antagonistic effect.
Nevertheless, we can conclude that there are
numerous cohort and case-control studies
proving the causal role of tobacco smoking
in the development of stomach cancer (not
systematically reviewed). The RR for
stomach cancer for the highest level of
tobacco use (~20 cigarettes/day) varied
according to 29 cohort and 45 case-control
studies from 0.7 to 12 (IARC, 2004).
In conclusion, there is strong, grade A level
of evidence indicating a significant
synergistic effect of alcohol and smoking on
all upper digestive tract cancers except
stomach cancer. Furthermore, data clearly
support the multiplicative effect of alcohol
and tobacco on cancer risk. Depending on
the anatomical site, the multiple-risk effect
varies, being in any case marked.
Figure 2. Multiplicative risk effect of smoking and alcohol consumption (expressed as relative risk,






















1.3 Effect of gene polymorphism on
alcohol-related upper digestive tract
cancers
There is strong recent epidemiological
evidence suggesting that the risk of alcohol-
related upper aerodigestive tract cancers is
markedly influenced by either a genetically
reduced ability to eliminate the first
metabolite of alcohol oxidation
acetaldehyde or an enhanced ability to
produce it. Therefore, two systematic
literature searches were carried out on this
topic.
1.3.1 ALDH-polymorphism
 A search from MEDLINE [*Alcohol
drinking OR alcoholism AND aldehyde
dehydrogenase AND neoplasm
(aetiology/epidemiology)] resulted in 33
studies of which 13 case-control studies,
(over 3245 subjects) examined upper
digestive tract cancers. In addition, two
studies and one meta-analysis (7 studies
with 905 cases); (Lewis and Smith, 2005)
were manually located. All but one (Katoh
et al., 1999) of the studies confirmed
increased upper digestive tract cancer risk
associated with  alcohol consumption and
the low-activity form of ALDH2. In
Yokoyama’s study, the RRs in ALDH2-
deficient subjects, after adjustment for
confounders, for oropharyngolaryngeal,
oesophageal, stomach, colon and lung
cancers were 11.1, 12.5, 3.5, 3.4 and 8.2,
respectively, compared with individuals
with normal enzyme activity (Figure 3)
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Figure 3. Increased risks for oropharyngolaryngeal, oesophageal, stomach, colon and lung cancers
(expressed as odds ratios, OR) in ALDH2-deficient subjects when compared with




Among Japanese male alcoholics, a strong
association have been noted between
inactive heterozygous ALDH2 and cancer of
the oral cavity/oropharynx (OR, 20.8) and
hypopharynx/epilarynx (OR, 28.9) (Nomura
et al., 2000; Yokoyama et al., 1998;
Yokoyama et al., 2001). In the presence of
the ALDH2*2 allele, the risk of field
cancerization is also markedly increased
(Morita et al., 1994; Schwartz et al., 1994;
Yokoyama et al., 1996b; Yokoyama et al.,
2002). This multiplicity of upper
aerodigestive tract cancers suggests a
common aetiology, thus supporting the role
of acetaldehyde in the carcinogenesis.
This conclusion is also supported by a recent
meta-analysis of alcohol, ALDH2 and
oesophageal cancer, including seven studies
carried out in Japan, Taiwan and Thailand.
A significantly increased oesophageal
cancer risk (OR, 3.19) was found in
ALDH2*1/*2 heterozygotes, which
provides evidence for the carcinogenic
action of acetaldehyde (Lewis and Smith,
2005). Already one of the very first studies
in which the association of increased cancer
risk related to acetaldehyde was discovered
showed increased oesophageal cancer risk in
alcoholics with the ALDH2*2 allele
(Yokoyama et al., 1996a).
1.3.2. ADH polymorphism
An ALDH2 deficiency is extremely rare in
the Caucasian population. However, a
polymorphism in the ADH enzyme may
have an increasing impact on the capacity to
produce acetaldehyde.
A MEDLINE search [*alcohol drinking OR
alcoholism AND alcohol dehydrogenase
AND neoplasms (aetiology, epidemiology,
genetics)] yielded 29 studies, 12 of which
were included here as they covered upper
digestive tract cancer risk and the ADH1C
allele (former ADH3). In a recent pooled
analysis including 1325 cases, the
ADH1C*1 allele was concluded not to
confer an increased risk for head and neck
cancers (Brennan et al., 2004). This analysis
missed, however, the two most recent
studies (Homann et al., 2005; Visapää et al.,
2004) in which a positive association was
found between the ADH1C*1 allele and the
risk of oesophageal, head and neck cancers.
The highest ORs for upper digestive tract
cancers were reported in a study from Puerto
Rico: 40.1 and 7.0 for homozygotic and
heterozygotic alcoholics, respectively for the
ADH1C*1 allele (Harty et al., 1997). A
positive association was also found in a
French study (Coutelle et al., 1997).
However, six other studies reported
conflicting results (Bouchardy et al., 2000;
Olshan et al., 2001; Risch et al., 2003;
Schwartz et al., 2001; Sturgis et al., 2001;
Zavras et al., 2002). In conclusion, the
association of ADH1C with alcohol-related
upper digestive tract cancer risk is under
debate, and further studies on this topic are
needed.
The IARC monograph on acetaldehyde also
pays attention to some (published before
1999) epidemiological studies reporting
increased cancer risk with ALDH2
deficiency or the ADH1C*1 allele.
Acetaldehyde was concluded to possibly be
carcinogenic to humans (IARC, 1999).
Moreover, acetaldehyde has been classified
as “reasonably anticipated to be a human
carcinogen” by the US government’s 9th
report on carcinogens (U.S. Department of
Health and Human Services, P.H.S.,
National Toxicology program, 2001
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2 ETHANOL METABOLISM IN THE GASTROINTESTINAL TRACT
A brief review of distribution and
metabolism of ethanol is given in this
section.
2.1 Distribution of ethanol
Ethanol is absorbed without transport
mechanisms, by simple diffusion from the
digestive tract because of its small
molecular size and good water solubility
(Crabb et al., 1987; Wallgren and Barry III,
1970). Of the ingested ethanol, 70-80 % is
absorbed from the proximal small intestine –
the duodenum and the upper jejunum. A
smaller proportion (~25 %) is absorbed from
the stomach. After absorption, ethanol is
distributed via blood circulation and
diffusion throughout the body fluids.
Distribution of alcohol is mainly related to
the water content of various organs and
tissues. Consequently, ethanol
concentrations after the distribution phase in
the digestive tract, e.g. in the ileum, (Halsted
et al., 1973) colon (Levitt et al., 1982)  and
oral cavity (Jones, 1979) are equal to those
in the blood. The high water content of
saliva and urine might even result in a
slightly higher ethanol concentration in
saliva than in blood (Bendtsen et al., 1999;
Jones, 1979).
Most of the ethanol (90-95%) is completely
metabolized in the body by oxidation and
excreted as carbon dioxide (CO2) and water.
A minor portion of ingested ethanol is
excreted unaltered via urine, sweat and
breath (Holford, 1987).
2.2 Ethanol and acetaldehyde metabolism
The liver is the main site for ethanol
metabolism. Under normal conditions, the
liver eliminates 75-90% of ethanol (Agarwal
and Goedde, 1990).  However, in severe
hepatic cirrhosis, extrahepatic elimination of
ethanol can account for up to 40% (Utne and
Winkler, 1980). Three metabolic pathways
are available for ethanol oxidation in the
liver: cytosolic alcohol dehydrogenase
(ADH), microsomal ethanol oxidizing
system (MEOS) and catalase; the ADH
pathway is the most important and effective
(Figure 4). All of these pathways yield
acetaldehyde as an end-product.
Acetaldehyde is further converted to acetate,
mainly by mitochondrial aldehyde
dehydrogenase.






 2.2.1 Alcohol dehydrogenase
ADH catalyses the reversible, NAD-
dependent oxidation of many alcohols to the
corresponding aldehydes. In the case of
ethanol, the reaction is as follows:
CH3CH2OH  + NAD ↔  CH3CHO  +
NADH+ H
ADH is abundant in the liver and its
physiological role has been postulated to be
the degradation of low levels of endogenous
ethanol produced by microbial fermentation
in the gut. Another possible role is the
degradation of endogenous steroids (Krebs
and Perkins, 1970). Human ADHs can be
grouped into five classes, I-V, based on the
characteristics of their primary structure
(Jörnvall and Höög, 1995). However, the
most important enzymes in hepatic ethanol
elimination are class I ADHs. These
enzymes, with both a low Km (~1 mM) and
a high Vmax for ethanol, are responsible for
the bulk of ethanol oxidation from the blood
(Blair and Vallee, 1966).Class I ADHs have
three isoenzymes: ADH1A, ADH1B and
ADH1C, which are expressed by three
genes. ADH1B and ADH1C are
polymorphic; for ADH1B, three different
(ADH1B*1,-*2,-*3) and for ADH1C
(ADH1C*1,-*2) two different allelic forms
have been found (Bosron and Li, 1986;
Duester et al., 1999). The clinical
significance of and interest in human ADHs
is based on differences in the ethnic and
racial distribution of these allelic forms. For
example, the frequency of the ADH1C*1
allele is approximately 50-60% in
Caucasians and more than 90% in Asians
(Bosron and Li, 1986). Furthermore, the
enzyme activities encoded by these different
allelic forms differ from each other;
individuals with the ADH1C*1/*1 genotype
are, for instance, able to metabolize ethanol
to acetaldehyde, at least in vitro 2.5 times
faster than individuals with other ADH1C
genotypes (Bosron and Li, 1986). This
genotype is more prone to digestive tract
cancers, as discussed earlier, probably due
to the above-mentioned genetic
characteristics, which are discussed further
in sections 3.3 and 4.2.
The other ADH classes (II-V) in humans are
expressed in the mucosa covering the human
digestive tract. The mucosa of the gingiva
and tongue expresses class III and class IV
ADH isoenzymes (Dong et al., 1996). The
main ADH isoenzyme in the oesophagus is
class IV (Yin et al., 1993). The stomach
expresses many ADH isoenzymes, of which
classes I and IV are postulated to be the
most important (Pares et al., 1992; Seitz and
Oneta, 1998; Yin et al., 1993). In
conclusion, it can be generalized that class
IV ADH is characteristic of the upper
digestive tract and class I of the rest of the
intestinal tract. The Km values for the
above-mentioned ADHs range from 1 to 40
mM, the highest values being in the upper
digestive tract and the lowest in the large
intestine (Seitz and Oneta, 1998). This is
logical as these ethanol concentrations
correspond to the in vivo amounts to which
the mucosa is exposed. While the exact in
vivo role of mucosal ADH remains obscure,
it is presumably involved in the regulation
of local acetaldehyde concentration in the
digestive tract (Visapää et al., 2002).
2.2.2 MEOS
In humans, estimations for the contribution
of the microsomal ethanol oxidizing system
(MEOS), the CYP2E1-cytochrome fraction,
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to the total ethanol metabolism vary widely,
from 3% to over 30% (Alderman et al.,
1987; Handler et al., 1988). It is suggested
that the MEOS contributes to ethanol
elimination only at higher blood ethanol
levels since its Km for ethanol is 7-10 mM.
CYP2E1 may, however, adapt to the
constantly high blood ethanol concentration
in chronic alcohol consumers (Lieber,
1988). The MEOS oxidizes ethanol to
acetaldehyde as follows:
     CH3CH2OH  + NADPH  +  H  +  O2 →
CH3CHO  +  NADP+ 2H2O
2.2.3 Catalase
Catalase, located in peroxisomes, can
oxidize ethanol to acetaldehyde when
hydrogen peroxide is available as follows:
    CH3CH2OH  +  H2O2 →  CH3CHO  +
2H2O
Since the reaction is limited by the
bioavailability of hydrogen peroxide and its
production in the liver is rather low, catalase
plays only a minor role < 2% in hepatic
ethanol metabolism (Boveris et al., 1972).
2.2.4 Aldehyde dehydrogenase
Regardless of the pathway by which ethanol
is oxidized, acetaldehyde is the first
metabolic product. The second reaction in
ethanol metabolism is the oxidation of
acetaldehyde to acetate by the aldehyde
dehydrogenase (ALDH) enzyme. In
humans, many ALDH isoenzyme classes
have been isolated.  The isoenzyme mainly
responsible for acetaldehyde oxidation is the
mitochondrial class II ALDH (ALDH2),
which has a micromolar Km value and a
high affinity for acetaldehyde (Lands, 1998).
Human ALDH2 enzyme is polymorphic,
with two allelic forms, ALDH2*1 and
ALDH2*2. The ALDH2*2 allele is the
result of a point mutation in the normal
allele. Individuals homozygous
(ALDH2*2/*2) for this mutated allele lack
ALDH activity, whereas heterozygous
individuals (ALDH2*1/*2) have 30-50% of
the activity of ALDH2*1 homozygotes
(Crabb et al., 1989). This mutation is
extremely rare in Caucasians but frequent in
Asians; for example 50% of the Japanese
population is ALDH2-deficient (Agarwal
and Goedde, 1992).
The homozygous form of inactive ALDH2
offers protection against alcoholism. This is
most probably due to the accumulation of
acetaldehyde during alcohol metabolism,
which causes aversive symptoms (Peng et
al., 1999). Heterozygote subjects can,
however, tolerate the unpleasant symptoms
caused by increased acetaldehyde levels, and
thus can drink alcohol or even develop
alcohol dependency (Wall et al., 1992).
Blood acetaldehyde levels in these
heterozygotes have been shown to be
between 8 and 24 µM, even after a very low
dose (0.1 g/kg of body weight) of ethanol
(Enomoto et al., 1991). Most importantly,
acetaldehyde concentration in the saliva of
these subjects is also elevated after ethanol
challenge due to diminished elimination of
acetaldehyde in the parotid glands
(Väkeväinen et al., 2000). By comparison,
normal healthy subjects have very low
levels (<0.5 µM) of acetaldehyde in their
blood during ethanol oxidation (Eriksson
and Fukunaga, 1993), and their salivary
acetaldehyde is only of microbial origin
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(Väkeväinen et al., 2001). As the mutation
in the ALDH2 gene results in impaired local
acetaldehyde metabolism, and consequently,
in increased acetaldehyde exposure after
alcohol consumption ALDH2*2
heterozygotic subjects can  be considered
partial knock-out models for the effects of
high levels of acetaldehyde. This
heterozygocity together with heavy drinking
induces a markedly increased risk for
gastrointestinal tract cancers compared with
individuals possessing the normal ALDH2
genotype (Yokoyama and Omori, 2003;
Yokoyama et al., 1998), as discussed earlier
and further described in sections 3.3 and 4.2.
2.3 Microbial ethanol metabolism
In addition to the liver, microbes in the
digestive tract are able to engage in ethanol
oxidation. To produce energy under
anaerobic conditions, microbes may degrade
sugars to ethanol. The last step in this
alcoholic fermentation is the reduction of
acetaldehyde to ethanol, catalysed by
bacterial ADH (Reid and Fewson, 1994).
This has been described in detail for
Escherichia coli (Clark, 1989), group N
Streptococci (Lees, 1976) and
Enterobacteriaceae in general (Salveson
and Bergan, 1981). Due to ongoing
microbial reactions, especially in the large
intestine, measurable amounts of ethanol are
formed in the gastrointestinal tract. This
endogenous ethanol is partly dissolved in
the portal blood circulation and thereafter
efficiently metabolized in the liver, never
reaching the systemic blood circulation
(Krebs and Perkins, 1970). However, under
some conditions associated with microbial
overgrowth, elevated endogenous ethanol
levels are detected even in blood (Kaji et al.,
1984).
An ADH-mediated reaction is reversible
also in microbes (Maconi et al., 1988). This
means that if oxygen and excessive ethanol
are present, the reaction can proceed in the
opposite direction, with ethanol being
oxidized to acetaldehyde. There are
numerous in vitro and in vivo studies
providing evidence for microbially mediated
acetaldehyde production in humans. Nosova
et al., for example characterized the ADH
activity and acetaldehyde production in vitro
of several bacteria representing human
microbiota (Nosova et al., 1997; Nosova et
al., 2000). Many different strains of faecal
E. coli and other Gram-negative rods,
mainly belonging to the enterobacteriaceae
family, produce significant amounts of
acetaldehyde when incubated aerobically in
vitro in the presence of ethanol (Jokelainen
et al., 1996). Human colonic contents
(mixture of colonic bacteria) produce
acetaldehyde from physiological levels of
ethanol in a dose-dependent manner
(Jokelainen et al., 1994). In vivo, ethanol
administration to pigs leads to a marked
increase in intracolonic acetaldehyde
concentration (Jokelainen et al., 1996b).
Similarly, high acetaldehyde levels are
detected in the caecal samples of rats after
an acute dose of ethanol (Visapää et al.,
1998).  The microbially mediated pathway
for ethanol metabolism can be modulated by
treatments with antibiotics or prebiotics.
Ciprofloxacin decreases the number of
aerobic bacteria in the large intestine and
this is associated with a significant decrease
in ethanol elimination rate and intracolonic
acetaldehyde production both in
experimental animals and in humans
(Nosova et al., 1999; Tillonen et al., 1999b).
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Similarly, lactulose decreases intracolonic
pH dependent ADH-mediated acetaldehyde
production in rats (Zidi et al., 2003).
Ethanol-derived acetaldehyde production
occurs also in the achlorhydric stomach
caused by atrophic gastritis or protein pump
inhibitors, which leads to bacterial
overgrowth in the neutral stomach
(Väkeväinen et al., 2000; Väkeväinen et al.,
2002).
In the upper digestive tract, significant
microbially mediated acetaldehyde
production is detected when human mouth
and bronchopulmonary washings are
incubated with ethanol in vitro (Jauhonen et
al., 1982; Miyakawa et al., 1986;
Pikkarainen et al., 1981). Furthermore, the
mouth washings of patients with
oropharyngeal cancer produce higher
amounts of acetaldehyde in vitro than those
of healthy controls (Jokelainen et al.,
1996a).  Increased in vitro acetaldehyde
production from ethanol is also observed in
heavy drinkers and smokers (Homann et al.,
2000). Smoking, alcohol consumption, poor
oral hygiene and differences in oral
microbial flora may thus influence local
levels of acetaldehyde in saliva and
consequently the whole upper digestive
tract. The role of these key factors in the
regulation of local acetaldehyde production
in the upper digestive tract will be discussed
in the next section.
3 ETHANOL AND ACETALDEHYDE AS CARCINOGENIC SUBSTANCES
3.1 Ethanol
Although the consumption of alcoholic
beverages is an established risk factor for
digestive tract cancers, there is no evidence
that ethanol itself is a carcinogen.
Systematic reviews have generally stated
that pure ethanol is not carcinogenic in
laboratory experiments (Doll et al., 1999;
IARC, 1988). However, many of the studies
described in the literature cannot be used for
the evaluation of carcinogenicity of alcohol
due to limitations in experimental design
(IARC, 1988). Based on limited data
available there is no experimental evidence
that alcohol itself is a carcinogen (Doll et
al., 1999).
On the other hand, evidence has emerged
that ethanol may act as a co-carcinogen in
the production of cancers. In the IARC
monograph, a large number of animal
studies indicate that ethanol modifies or
enhances the carcinogenic potential of
known carcinogens (IARC, 1988). Many
more or less indirect mechanisms by which
chronic alcohol consumption may stimulate
carcinogenesis also exist. However, this
topic is not systematically reviewed or
discussed in detail in this thesis. In brief,
these potential mechanisms include (i) local
direct mucosal damage and actions of
alcohol as a solvent for carcinogenic
compounds (Albanes and Winick, 1988;
Blot, 1992; Cohen and Ellwein, 1990; Maier
et al., 1986; Salo, 1983), (ii) induction of
cytochrome P-4502E1, which produces free
radicals and activates precarcinogens
(Albano and Clot, 1996; Eskelson et al.,
1993; Seitz et al., 1998), (iii) nutritional
deficiencies in heavy drinkers (Seitz and
Suter, 2002; Seitz et al., 1998), (iv)
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alterations in the metabolism of retinal and
retinoic acid (Pöschl and Seitz, 2004), (v)
congeners in alcoholic beverages possible
acting as mutagens (Lieber et al., 1986), (vi)
immunosuppression induced by chronic
alcoholism (Palmer, 1978; Pöschl and Seitz,
2004), (vii) alterations in hormone status,
e.g. increased oestradiol levels in women
(Singletary and Gapstur, 2001) and (viii)
interaction of alcohol and/or acetaldehyde
with folate metabolism. The antagonist
effect of alcohol on folate status has been
known for two decades (Halsted et al., 2002;
Hillman and Steinberg, 1982). The risk of
colon cancer has also been shown to be
higher in persons with low folate status and
high alcohol consumption than in alcohol-
consuming persons with high folate status
(Giovannucci et al., 1995; La Vecchia et al.,
2002).  There are several mechanisms that
might contribute to the folate deficiency
associated with alcohol consumption and
cancer. One of these is the ability of
acetaldehyde to cleave folate (Shaw et al.,
1989). Accordingly, local acetaldehyde
production by microbes in the large intestine
might contribute to the risk of mucosal
neoplasia (Giovannucci, 2004; Homann et
al., 2000).
In conclusion, the lack of carcinogenicity of
alcohol itself in animal studies and the
failure of studies to fully elucidate the
mechanisms by which  ethanol acts as a co-
carcinogen provide evidence for the
important role of acetaldehyde in inducing
carcinogenicity of alcohol consumption.
3.2. Acetaldehyde
In most of the in vitro studies with human
and other mammalian cells, ethanol alone
has been shown not to induce DNA damage,
sister chromatid exchanges or chromosomal
aberrations (IARC, 1988).  On the other
hand, sister-chromatid exchanges are seen in
vitro when the alcohol dehydrogenase
enzyme is added together with ethanol to the
experimental system, resulting in the
production of acetaldehyde (Obe et al.,
1986).
Acetaldehyde is a highly toxic and reactive
compound, which has been linked to several
toxic effects associated with heavy drinking.
In addition to a large number of in vitro and
in vivo experimental studies, there is
increasing epidemiological and biochemical
evidence regarding the carcinogenicity of
acetaldehyde in humans due to impaired or
enhanced acetaldehyde metabolism.  To
elucidate the role of ethanol-derived
acetaldehyde in the carcinogenicity of
alcohol drinking, a systematic review on the
mutagenic and toxic effects of acetaldehyde
was executed.
 A MEDLINE search with the terms:
*acetaldehyde (toxicity) OR *acetaldehyde
AND mutagenesis OR metaplasia resulted in
36 publications. To also cover the very latest
studies, a search was performed in PubMed
(limited to publications from 1999 onwards)
with the terms acetaldehyde AND
mutagenesis OR carcinogenesis [78].
The IARC has also reviewed the
carcinogenicity data of acetaldehyde in
1985, 1987 and 1999. Thus, to avoid an
enormous number of references, this review
was limited to the IARC monograph and to
the studies published after that (i.e. from
1998 onwards). All studies published as an
original article were included. Studies
reporting neurotoxicity, teratogenesis of
acetaldehyde or tobacco smoke-derived
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acetaldehyde were excluded, as they are
discussed in the section 3.3. The search was
complemented with manual searches of




The IARC monograph contains 56 in vitro
studies concerning the harmful genetic
effects of acetaldehyde. These include test
systems in which acetaldehyde was tested
with bacteria, or with human or animal cells.
Thirty-seven of these studies concluded that
acetaldehyde had harmful effects. The
majority of the reverse mutation tests in
which Salmonella typhimurium or
Escherichia coli were incubated with
acetaldehyde (concentrations 55 – 200 µM)
failed, i.e. a reverse mutation was not
induced. This test is, in general, used to
detect possible point mutations induced by
chemicals.
However, a weak, positive, forward
mutation (a mutation that converts a wild-
type allele to a mutant allele) was detected
in Saccharomyces cerevisiae with 0.5 mM
acetaldehyde. It should be noted that the in
vitro bacterial mutation test cannot provide
direct information about the mutagenic
potency of a substance in mammals.
Acetaldehyde as a toxic compound has been
suggested to induce the expression of
acetaldehyde-detoxifying genes in microbes,
leading to acetaldehyde trapping with e.g.
sulphur-containing amino acids. Thus,
microbes in the ethanol/acetaldehyde-
containing environment can tolerate
acetaldehyde (Aranda and del Olmo, 2004).
On the other hand, acetaldehyde (4.4 and 4.5
mM concentrations, respectively) induced
chromosome malsegregation in Aspergillus
nidulans (Crebelli et al., 1989) and was
mutagenic in Drosophilia melanogaster
(Woodruff et al., 1985).
In studies with mammalian cells,
acetaldehyde induced DNA-protein cross
links to rat nasal mucosal cells, sister
chromatid exchanges in hamster ovary cells
and mouse bone-marrow cells both in vitro
and in vivo.  Also aneuploidy and
chromosomal aberrations were detected in
mammalian fibroblasts in vitro. These
mutagenic effects occurred at acetaldehyde
concentrations from 30 µM to 1000 µM.
There are numerous studies in which sister
chromatid exchanges (i.e. reciprocal
exchanges of DNA between two sister
chromatids of a duplicating chromosome)
have been detected in human lymphocytes
in vitro at very low acetaldehyde
concentrations (~88 µM) (IARC, 1999).
Furthermore, gene mutations and
chromosomal aberrations are induced with
0.2-0.3 mM acetaldehyde. Acetaldehyde
caused DNA strand breaks and cross links in
human lymphocytes in vitro, which were
not, however, detected in human bronchial
epithelial cells (IARC, 1999). When human
lymphocytes and digestive tract mucosal
cells are exposed to ethanol and
acetaldehyde in vitro, cell viability
decreases and DNA strand breaks are
observed; however, the specific effects of
ethanol or acetaldehyde cannot be clearly
determined (Blasiak et al., 2000).
Evidence from alcoholics and experimental
animal models indicates that acetaldehyde
and aldehydic products of lipid peroxidation
can bind to proteins, forming many types of




hydroxynonenol and hydroxyethyl radicals
(Freeman et al., 2005). Adduct formation
may lead to several adverse consequences,
such as interference with protein function,
stimulation of fibrogenesis and induction of
immune responses (Niemelä, 1999). As
stated earlier, ethanol is oxidized to
acetaldehyde also by the microsomal ethanol
oxidizing system (MEOS). This results in
the production of reactive oxygen
metabolites and in oxidative stress.
Acetaldehyde can also induce lipid
peroxidation. The mechanism underlying
this has been hypothesized to be
acetaldehyde’s capacity to reduce hepatic
glutathione levels (Shaw et al., 1981;
Situnayake et al., 1990). Lipid peroxidation
can generate aldehydes, 4-hydroxynonenal
and malondialdehyde. These reactive
products in addition to acetaldehyde can
then interact with amino acids, attacking the
nucleophilic groups of proteins to form
stable or unstable adducts (Niemelä et al.,
2002; Niemelä, 2001; Tuma, 2002). The
formation of acetaldehyde-protein adducts is
best described in the liver, alcoholic
cardiomyopathy and alcoholic skeletal
muscle myopathy (Niemelä, 1999; Patel et
al., 2005; Thiele et al., 2004). Their
formation in vivo and the relative
importance in carcinogenesis remain largely
unclear (Freeman et al., 2005).
Acetaldehyde also interacts with DNA,
producing DNA adducts. The covalent
binding of acetaldehyde to DNA and the
formation of stable adducts is one
mechanism by which it could induce
replication errors or mutations in oncogenes
or tumour-suppressor genes. This is
considered to be a critical event in chemical
carcinogenesis related to alcohol
consumption (Vaca et al., 1995). The best-
studied acetaldehyde-DNA adduct is N-
ethyl-2-deoxyguanosine. This adduct is
detected in vitro when calf thymus or pure
DNA is incubated with millimolar
concentrations of acetaldehyde (Fang and
Vaca, 1995). This adduct is also found in the
DNA of human buccal cells  following
exposure to acetaldehyde as well as in
human urine and  white  cells of alcohol
abusers in vivo (Brooks and Theruvathu,
2005; Fang and Vaca, 1997; Matsuda et al.,
1999; Vaca et al., 1998). Furthermore, three
stable DNA adducts are formed when calf
thymus is incubated with rather high, non-
physiological acetaldehyde concentrations
(up to 40 mM) (Wang et al., 2000). The
contribution of these DNA adducts to
cytogenetic abnormalities is unclear since
data with regard to adduct-induced errors in
DNA replication and synthesis are
controversial (Matsuda et al., 1999; Perrino
et al., 2003; Terashima et al., 2001).
Acetaldehyde may also inhibit the function
of the human DNA repair enzyme, 06
methyl-guanine transferase, in vitro and in
vivo already at a 0.01 mM concentration
(Espina et al., 1988). Concentrations of 1-5
mM acetaldehyde activate the expression
and activity of oncogenic transcription
factor Jun/AP-1 in oral keratinocytes, thus
acting as a tumour-promoting agent
(Timmons et al., 2002). Furthermore,
acetaldehyde treatment of human cells
yields specific tandem base (GG to TT)
substitutions in DNA. These mutations have
also been found in upper digestive tract
cancers (Matsuda et al., 1998). The
mutational spectrum induced by
acetaldehyde in vitro appears to resemble
that of the p53 gene of oesophageal tumours
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(Noori and Hou, 2001). This comparison,
however, does not take into account the
possible exposure to other carcinogens. In
addition to the initiation of carcinogenesis,
acetaldehyde may intensify the tumour
development in vitro by increasing the
proliferation rate of Caco-2 cells, reducing
their adhesion and disturbing their
differentiation (Koivisto and Salaspuro,
1998).
Very recently, a novel mutagenic
mechanism induced by acetaldehyde has
been suggested. With biologically relevant
acetaldehyde concentrations (from 50-100
µM),  polyamines were found to facilitate
the formation of -methyl- -hydroxy-1,n-
propano-2-deoxyguanosine adducts, which
previously have been detected only at
supraphysiological (40 mM) concentrations
of acetaldehyde. Furthermore, the
polyamine spermidine reacted directly with
acetaldehyde, generating crotonaldehyde
(Theruvathu et al., 2005). Thus, in addition
to direct adduct formation, acetaldehyde can
be converted to crotonaldehyde by
polyamines, forming crotonaldehyde
adducts, which might contribute to the
carcinogenicity of acetaldehyde in vivo in
the digestive tract.
3.2.2 Acetaldehyde-related
carcinogenicity in experimental animals
The carcinogenicity of acetaldehyde has
been tested in several animal exposure
experiments. In the IARC monograph, there
is an extensive review of the topic.
Acetaldehyde produces tumours of the
respiratory tract by inhalation exposure. An
increased incidence of laryngeal carcinomas
in hamsters and adeno and squamous cell
carcinomas of the nasal mucosa in rats are
induced by inhalation exposure to
acetaldehyde. However, another inhalation
study with a lower acetaldehyde
concentration and a study with intratracheal
installation of acetaldehyde did not report
increased tumour incidence.  In these
studies, acetaldehyde concentrations varied
from approximately 30 µM to 130 µM and
exposure times were 6-7 hours per day on 5-
7 days per week. In hamsters, inhalation of
acetaldehyde enhanced the incidence of
respiratory tract tumours produced by
benzo(a)pyrene (Feron et al., 1991; IARC,
1985; IARC, 1999; Woutersen et al., 1986).
In the latest long-term experimental study in
which acetaldehyde was given to rats for
161 weeks in tap water ad libitum in
concentrations approximately from 1 mM to
56 mM, the total number of malignant
tumours increased in all but one group. In
particular, an increased incidence of
carcinomas of nasal sinuses and oral cavity
was detected in the groups treated with the
highest dose (Soffritti et al., 2002).  In an
earlier study, hyperplastic and
hyperproliferating changes in the tongue,
epiglottis and forestomach were detected in
rats receiving acetaldehyde (120 mM
concentration) in tap water for eight months
(Homann et al., 1997).
In conclusion, these studies strongly support
the statement of the IARC that sufficient
evidence exists in experimental animals to





Human exposure data with acetaldehyde is
naturally scarce, since it would be unethical
to conduct an exposure study – even for a
short period – with a carcinogenic
substance. However, an interesting finding
was made in a survey at a chemical plant
where workers were exposed to abnormally
high concentrations of aldehydes such as
acetaldehyde. Nine cancer cases were found
among these workers. Of the cancer cases,
five were bronchial tumours and two oral
cavity carsinomas (IARC, 1985). Despite
deficiencies in the study setting (poorly
defined exposures, small number of cases),
this finding supports the carcinogenic
actions of acetaldehyde in humans.
As mentioned above, no proper human
experimental studies exist on this topic.
However, the natural genetic polymorphism
of alcohol-, and acetaldehyde-metabolizing
genes offers a human model for the
carcinogenic effects of increased
acetaldehyde exposure. As stated in the
sections 1.3 and 2.2 and to be further
discussed in the section 4.2, recent
epidemiological and biochemical studies on
ALDH2-deficient Asian and Caucasian
alcoholics with high active ADH strongly
support the role of acetaldehyde in alcohol-
related digestive tract cancers.
In conclusion, strong evidence has been
provided by experimental studies and human
genetic models with different acetaldehyde
exposures that acetaldehyde is a
carcinogenic substance. Data on
acetaldehyde-related carcinogenicity is
summarized in Table 1.
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Table 1.
Summary of acetaldehyde-related carcinogenicity in vitro and/or in vivo
(Only key references presented in parenthesis)
Experiment/test system Result
IN VITRO
Bacterial cell cultures - Gene mutation
- Aneuploidy
  (IARC, 1999)
Human/animal cell cultures - Mutations/tandem base substitutions
- Sister chromatid exchange
- DNA-protein cross links
- Chromosomal aberrations
- Protein adducts
- DNA strand breaks
- DNA adducts
- Activation of oncogenes
- Interaction of polyamines, facilitating
adduct formation
   (IARC, 1999; Theruvathu et al., 2005)
IN VIVO
Cell damage in vivo - DNA adducts in leukocytes of
alcoholics
   (Fang and Vaca, 1997)
Inhalation exposure in animals - Laryngeal carcinomas in hamsters
- Nasal-mucosal carcinomas in rats
   (Feron et al., 1982; Woutersen et al.,
1986)
Oral (drinking water) exposure in animals - Carcinomas of nasal sinuses and oral
cavity in rats
- Hyperplastic and hyperproliferating
changes in tongue, epiglottis and
forestomach (Homann et al., 1997a)
Human “knock-out” model for increased
acetaldehyde exposure during alcohol ingestion
of individuals with impaired acetaldehyde
metabolism (ALDH2 deficiency)
- Markedly increased cancer risk in
upper digestive tract compared with
individuals with normal acetaldehyde
metabolism
   (Yokoyama and Omori, 2005;
Yokoyama et al., 1998)
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3.3 Tobacco smoking and acetaldehyde
As reviewed in previous sections,
acetaldehyde is the major carcinogenic agent
associated with alcohol-related upper
aerodigestive cancers. However,
acetaldehyde is also a well-known
constituent of tobacco smoke. Since alcohol
consumption often goes hand in hand with
tobacco smoking and both are major risk
factors for upper digestive tract cancers, a
systematic review from the MEDLINE
database was executed in order to clarify the
relationship between acetaldehyde and
smoking. The search of
Tobacco smoke OR smoking AND
Acetaldehyde [59]
resulted in 59 studies, 19 of which were
included in this review. Inclusion criteria
comprised tobacco-derived acetaldehyde
formation, concentration and possible
effects in vitro and in vivo. The IARC
monograph from 2004 on tobacco smoke
and involuntary smoking was also included,
as it presents some data on acetaldehyde as a
constituent of tobacco smoke. Studies
covering strict analytical methods or
elimination of acetaldehyde (discussed in
section 4.4) were excluded.
An estimated 4800 compounds are present
in cigarette smoke, and 3044 constituents
have been isolated from tobacco (Hoffmann
and Hoffmann, 1997; IARC, 2004).
Cigarette smoke contains several aldehydes
generated by the combustion of organic
material. Formaldehyde and acetaldehyde
are listed as carcinogens in the IARC
monograph. Other toxic aldehydes such as
acrolein and crotonaldehyde have also been
found from the tobacco smoke (Hoffmann
and Hoffmann, 2001; Smith et al., 2003).
According to the IARC, the number of
identified carcinogens in tobacco smoke was
69 in the year 2000. Eleven of these are
known carcinogens and seven probable
carcinogens in humans. Forty-nine are
animal carcinogens and possibly also
carcinogenic to humans (IARC
Classification) (IARC, 2004). The exact
number of human carcinogens is, however,
unknown, since tobacco smoke contains
over 80 toxic substances that could
potentially act as carcinogens (Smith et al.,
2003). Acetaldehyde is included in
carcinogenic substances in tobacco
mainstream smoke (MS) (Fowles and
Dybing, 2003; Hoffmann and Hoffmann,
2001; Hoffmann et al., 2001). These
carcinogens include 10 polynuclear (also
called polycyclic) aromatic hydrocarbons
(PAHs), six heterocyclic hydrocarbons, four
volatile hydrocarbons, three
nitrohydrocarbons, four aromatic amines,
eight N-heterocyclic amines, 10 N-
nitrosamines, two aldehydes (formaldehyde
and acetaldehyde) and 10 miscellaneous
organic, nine inorganic and three phenolic
compounds (IARC, 2004). The most
abundant of these carcinogens is
acetaldehyde. Its concentration in non-filter
cigarettes ranges from 500µg to 1400 µg.
The concentration of acetaldehyde in
cigarette smoke is more than 1000 times
greater than that of PAHs and tobacco-
specific nitrosamines (Hoffmann and
Hoffmann, 2001). Thus, the concentration of
acetaldehyde in mainstream smoke is far
greater than the concentrations of the other
carcinogenic substances (Rustemeier et al.,
2002). Although the absolute concentration
of a toxic substance is not directly
comparable with its toxicity in humans, the
amount of acetaldehyde in a single cigarette
is far greater than that measured in humans
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during ethanol elimination (to be discussed
further in later sections).
When hazard prioritization for reported
chemical constituents of cigarette smoke
using toxicological risk assessment was
provided by Fowles et al., aldehydes and
small organic compounds were described as
the main contributors to the overall cancer
risk index (calculated by multiplying yield
levels with cancer potency factors) (Fowles
and Dybing, 2003). Moreover, acetaldehyde
was placed in the first toxicity category with
fifteen other substances (Smith and Hansch,
2000). In conclusion, besides acetaldehyde,
many other toxic and carcinogenic
substances are present in the mainstream
smoke of cigarettes. It is impossible to
evaluate the contribution of a single
substance to the total carcinogenic effect.
However, reducing the toxic potency of
cigarette smoke might be possible, if the
most significant causative agents of cancer
could be identified and reduced. This will be
further discussed in the sections covering
the regulation of local acetaldehyde
concentration in saliva.
As acetaldehyde is primarily in the gas
phase, it is retained in the aerodigestive tract
of smokers. As early as 1968, it was
reported that 60% of acetaldehyde delivered
in tobacco smoke is retained in the mouth
(Dalhamn et al., 1968a). Another study
assessed the retention of acetaldehyde to be
99% during inhalation of cigarette smoke
(Dalhamn et al., 1968b). Although there is
marked retention of acetaldehyde during
smoking, this is not reflected in an increase
in systemic blood acetaldehyde of smokers.
This is understandable since acetaldehyde is
a reactive and soluble substance acting
locally.  Acetaldehyde derived from
smoking has previously been measured from
the breath and saliva. After smoking a
cigarette, breath acetaldehyde concentration
is increased sixfold and that of saliva
twofold (Annovazzi et al., 2004;
McLaughlin et al., 1990). In the airways,
acetaldehyde when inhaled has been shown
to induce histamine-related
bronchoconstriction in humans (Myou et al.,
1993; Sanchez-Toril et al., 2000).
Few studies have tested the toxic effects of
the aldehyde mixture present in tobacco
smoke in cell cultures. In in vitro
experiments, acetaldehyde and acrolein
inhibit human bronchial epithelial cell repair
processes similarly, to whole-cigarette
smoke condensate (Wang et al., 2001).
However, two other studies with
acetaldehyde failed to induce radical toxic
effects on a human b-cell line or on mouse
lymphocytes. On the other hand, mixtures of
different aldehydes (acetaldehyde, acrolein,
formaldehyde, propionaldehyde) were able
to significantly inhibit cell proliferation
(Poirier et al., 2002) and to induce direct
DNA damage (Yang et al., 1999). Acrolein
was found to be a more potent toxicant than
formaldehyde and acetaldehyde to human
bronchial fibroblasts after treatment with
micromolar concentrations. Furthermore,
these aldehydes markedly inhibited the
DNA repair enzyme methyl-guanine-DNA
methyltransferase, as pointed out previously
with acetaldehyde (Krokan et al., 1985). In
addition, acetaldehyde and acrolein were
observed to have cytotoxic effects, with
disturbed adhesion and viability of cultured
human gingival fibroblasts (Poggi et al.,
2002). There may, however, be some flaws
in in vitro cell studies since they have failed
to show toxic effects of other toxicants in
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cigarette smoke, e.g. benzene and styrene
(Poirier et al., 2002).
The toxicity of tobacco smoke related to
acetaldehyde is also related to the combined
actions of other harmful substances in the
tobacco smoke. One of these is the
interaction of acetaldehyde with PAH
compounds by enhancing the formation of
benzo[a]pyrene DNA adducts (Barnes et al.,
2000). The interaction of formaldehyde and
acetaldehyde also produces newly identified
cyclic deoxyguanosine adducts and
formaldehyde cross links (Cheng et al.,
2003). Aldehyde-derived promutagenic
adducts have been found in smokers in vivo.
Acrolein- and crotonaldehyde-derived
propanodeoxygaunosine adducts were
significantly higher in the DNA of gingival
tissue of smokers than non-smokers (Nath et
al., 1998). Even though in vivo studies
concerning possible acetaldehyde-induced
adducts in smokers’ tissues were not found,
the presence of such adducts can be
expected since adduct formation of
acetaldehyde with DNA has clearly been
shown in vitro and also found in vivo in
alcoholics.
In conclusion, considering the high exposure
of smokers to acetaldehyde, acetaldehyde is
likely to be a substantial factor behind
smoking-related carcinogenic and other
toxic effects.
4 REGULATION OF LOCAL ACETALDEHYDE
CONCENTRATION IN THE UPPER DIGESTIVE TRACT
This last section will systematically review
the known factors or individual
characteristics by which local acetaldehyde
concentration is regulated in the upper
digestive tract. By affecting levels of
carcinogenic acetaldehyde, one might be
able to influence the risk of upper digestive
tract cancer.
4.1 Role of microbes and oral hygiene
Human oral flora is known to contain over
350 cultivatable species (with another 50%
uncultivatable by current techniques), and
the bacteria may grow as densely as in the
colon. The composition of oral flora,
however, varies from place to place in the
mouth. Thus, tooth surfaces, the buccal
mucosa, the surface of the tongue and the
pharynx all have different and characteristic
flora. Many bacteria of the oral flora are
facultative or aerobic bacteria, thus being
able to produce acetaldehyde in the oral
cavity with their ADH enzyme (Bagg et al.,
1999). Consequently, oral microbes may
have an essential contribution to the local
acetaldehyde production individually. On
the other hand, poor dental health associated
with bacterial overgrowth is a risk factor for
cancer of the mouth in alcoholics (Maier et
al., 1993). To elucidate the regulatory role
of microbes and oral hygiene in local
acetaldehyde levels in the upper digestive
tract, a systematic review was executed as
follows:
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Mouth OR pharynx OR larynx OR
oesophagus
AND
Microbes OR Bacteria OR Fungi
AND
Acetaldehyde [4]
As a result, four studies were found from the
MEDLINE and one additional study from
the PUBMED.
Homann et al. have intensively studied the
contribution of oral bacteria and hygiene to
the local acetaldehyde production. First of
all, they demonstrated a marked
acetaldehyde production in saliva after
ingestion of a moderate amount of ethanol
(Homann et al., 1997b). Furthermore,
considerable interindividual variation in
acetaldehyde production capacity was also
detected. This acetaldehyde production was
significantly reduced after a three-day use of
an antiseptic mouthwash – chlorhexidine
(Homann et al., 1997b). This is a strong
indicator that acetaldehyde production is of
microbial origin. In vitro acetaldehyde
production was also shown to correlate with
the ethanol concentrations, to be linear over
time and not be saturated under
physiological ethanol conditions. The
microbial acetaldehyde production is also
supported by Muto’s results, in which a
certain Neisseria was identified from the
human oral flora to possess extremely high
ADH activity. This bacterial strain was also
able to produce clinically significant
amounts of acetaldehyde and more than
100-fold higher acetaldehyde levels (23
µM/min/1011 CFU) than other strains.
Furthermore, alcohol ingestion influences
the bacterial composition of the oral
microbiota, resulting in an increased
proportion of non-pathogenic Neisseria
(Muto et al., 2000). Yeasts may also
significantly contribute to local
acetaldehyde levels in the oral cavity. Some
C. albicans strains, restricted from human
saliva, have a marked capacity to produce
acetaldehyde from ethanol in vitro (Tillonen
et al., 1999a).
Some evidence exists that bacterial
overgrowth in patients with poor oral
hygiene influences local acetaldehyde
production in the mouth. A recent study in
which the role of dental status in microbial
production of acetaldehyde was evaluated,
showed that poor dental status leads to a
twofold increase in in vitro salivary
acetaldehyde production from ethanol
(Homann et al., 2001). Furthermore,
microbiological analysis of “high” and
“low” acetaldehyde-producing salivas
obtained from human volunteers
demonstrated that several bacterial strains
were associated with increased acetaldehyde
levels. “High acetaldehyde producers” were
for instance Streptococcus salivarius, alpha-
hemolysing Streptococci, Corynebacterium
ssp. and Stomatococcus (Homann et al.,
2000). The last study included in the review
dealt with the invention of an antimicrobial
agent, chlorhexidine, formulated as a
controlled-release chip and fixed with a
dental device. It was hypothesized that this
might be a rational strategy for reducing
acetaldehyde production by oral microbiota
(Rota and Poggi, 2003).
In conclusion, large interindividual
variations are present in oral acetaldehyde
levels after consumption of alcohol, and oral
microbes have an essential role in
acetaldehyde production in the oral cavity.
In addition, evidence is available for the
contribution of poor dental hygiene to
acetaldehyde production in the mouth.
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Whether a certain strain or the total number
of bacteria is more important in the
regulation of individual acetaldehyde levels
in saliva remains unknown.
4.2 Role of genetic factors
As stated in previous sections, in addition to
environmental factors, genetic differences in
alcohol- and acetaldehyde-metabolizing
enzymes may have an influence on
acetaldehyde production in the oral cavity.
To further elucidate the role of genetic
factors in the regulation of local
acetaldehyde levels in the upper digestive
tract, the literature was systematically
reviewed as follows:
Mouth OR pharynx OR larynx OR
oesophagus
AND




As a result, three studies were found (Muto
et al., 2000; Seitz and Pöschl, 1997;
Väkeväinen et al., 2000); the first was a
review and the second was excluded since it
investigated Neisseria’s acetaldehyde
production and  was already discussed in the
previous section. Due to the low number of
MEDLINE results, the search was executed
also in PUBMED. No studies concerning
local acetaldehyde concentrations in the
upper digestive tract in relation to ADH or
ALDH were found. However, one study was
found dealing with the expression of
ALDH2 in the mucosa of cancer patients in
relation to alcohol consumption (Morita et
al., 2005). This study did not report in vivo
acetaldehyde levels but was included in the
review, since the finding could be attributed
to local acetaldehyde. Results were
complemented with a manually selected
study in which the association of ADH1C*1
allele and salivary acetaldehyde was
determined (Visapää et al., 2004).
Individuals with a mutated ALDH2 allele
have increased systemic acetaldehyde levels
during ethanol metabolism (Luu et al., 1995;
Meier-Tackmann et al., 1990; Peng et al.,
2002). For ALDH2*2 heterozygotes, the
ingestion of 0.4 g of ethanol per kg of body
weight results in a mean blood acetaldehyde
level of approximately 23 µM (Mizoi et al.,
1994). This is a significant concentration
compared with the negligible levels of blood
acetaldehyde during ethanol metabolism in
individuals with normal ALDH2 enzyme
activity (Sarkola et al., 2002). However,
Väkeväinen et al., showed that the local
acetaldehyde concentration in saliva after a
dose of ethanol (0.5 g/kg of body weight) is
approximately ninefold higher than blood
acetaldehyde levels in ALDH2-deficient
heterozygotes. Furthermore, the salivary
acetaldehyde concentration in these flushers
was two to three times higher than in
subjects without the mutated allele
(Väkeväinen et al., 2000).
Salivary acetaldehyde concentration has
been demonstrated to be significantly
modulated by the ADH1C genotype.
Subjects homozygous for the ADH1C*1
allele have significantly higher salivary
acetaldehyde concentrations following
alcohol ingestion than non-homozygotes
(Visapää et al., 2004). However, no
differences in blood acetaldehyde levels
were observed between individuals with
different ADH genotypes. Furthermore, a
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significant correlation between salivary
acetaldehyde and salivary ethanol levels was
found in all subjects. Only subjects with the
ADH1C*1,1 genotype produced
significantly more salivary acetaldehyde
than the other genotypes. It was also
illustrated that even with high salivary
ethanol concentrations (40-50 mM) the
respective acetaldehyde concentration curve
did not seem to plateau, suggesting that
acetaldehyde formation was saturated.
Changes in salivary acetaldehyde in this
case probably could not be explained by
changes in oral mucosal ethanol metabolism
since class I ADH is not expressed in the
oral mucosa (Yin et al., 1997). However,
acetaldehyde might be produced in the
salivary glands, as shown in the case of
ALDH2-deficient subjects (Väkeväinen et
al., 2000). On the other hand, both inactive
and active forms of ALDH2 are induced in
the oesophagus by heavy drinking,
suggesting the accumulation of acetaldehyde
locally (Morita et al., 2005). Thus, this
finding supports the substantial role of
alcohol and acetaldehyde metabolism in the
regulation of acetaldehyde levels in the
upper digestive tract.  However, the
contribution of mucosal enzyme activity to
local acetaldehyde levels remains to be
elucidated.
To summarize, there is strong evidence that
genetic differences in ethanol- and
acetaldehyde-metabolizing enzymes
influence local acetaldehyde concentrations
in the upper digestive tract. Thus, increased
acetaldehyde levels in the saliva of ALDH2-
deficient and ADH1C*1-1 subjects could be
a major contributor to the increased cancer
risk associated with ethanol consumption in
these individuals. This concept is supported
by epidemiological studies (section 1.3)
showing that cancer risk in these subjects is
particularly increased in the upper digestive
tract, but not for example in the liver.
4.3 Role of tobacco smoking
As mentioned earlier, acetaldehyde is one of
the main substances in tobacco smoke.
Thus, smokers are exposed to this
carcinogenic agent during inhalation of
tobacco smoke. To evaluate the exposure of
the human upper digestive tract to tobacco
smoke-derived acetaldehyde, a systematic
review was executed from the MEDLINE
database as follows:
*Gastrointestinal tract AND tobacco OR
smoking AND acetaldehyde [8].
Eight studies were found. Four of these were
in vitro studies investigating the actions of
cigarette smoke on human fibroblasts, and
thus, have been referred to already. As a
result, four studies from the MEDLINE
search and two manually selected studies
(Annovazzi et al., 2004; Seeman et al.,
2002) were included in the review.
Smoking has been demonstrated in vitro to
significantly increase salivary acetaldehyde
production from ethanol. Smoking showed a
positive linear correlation with salivary
acetaldehyde and a smoker with a daily
consumption of ~20 cigarettes was
estimated to have an increased in vitro
salivary acetaldehyde production of ~50-
60% (Homann et al., 2000). In that study,
the additional acetaldehyde was produced by
the oral microbiota, and qualitative changes
described in the oral flora of smokers were
suggested to contribute to the increased
acetaldehyde production.
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Earlier in vivo evidence has indicated that
acetaldehyde is markedly retained in
smokers during cigarette smoking (Dalhamn
et al., 1968a; Dalhamn et al., 1968b).
However, systemic acetaldehyde levels are
not elevated. Acetaldehyde levels in the
breath have been shown to be significantly
increased immediately after smoking
(McLaughlin et al., 1990).
The retention of acetaldehyde in the upper
digestive tract is supported by the only study
found (in the review search) measuring
aldehyde concentrations after smoking in
vivo (Annovazzi et al., 2004). Acetaldehyde,
formaldehyde and acrolein were measured
from the saliva of smokers and non-smokers
and from non-smokers after smoking one
cigarette. The salivary aldehyde
concentration of regular smokers was
twofold higher than that of non-smokers.
Moreover, the acute smoking of a cigarette
increased the aldehyde concentration of
saliva to 3.5-fold.  However, the enormous
baseline variation in the salivary
acetaldehyde levels (from 21 µM to 463
µM) in study subjects is noteworthy. This
could at least in part be due to the
uncontrolled acetaldehyde formation in the
saliva, e.g. by oral microbiota. Thus, it
would be logical to conclude that a
significant amount of acetaldehyde from
tobacco smoke is dissolved in the upper
digestive tract during smoking.
4.4 Role of cysteine as an acetaldehyde-
binding agent
A short introduction to cysteine is given
before the systematic review.
Cysteine is a sulphur-containing amino acid.
With respect to human physiology, it is
considered semiessential since it can be
synthesized from methionine and serine via
transsulphuration. Cysteine is normally
consumed as a component of dietary
proteins. The estimated average intake of
cysteine is 1.3 g/day and 0.8 g/day in men
and women, respectively. Dietary cysteine is
absorbed as cysteine, cystine (two cysteine
molecules attached by disulphide linkage)
and cysteine-containing peptides. A
substantial proportion of ingested free,
sulphur containing amino acids are removed
from portal circulation by the liver. In vivo,
cystine  the oxidized form of cysteine is a
more stable compound than cysteine; the
respective plasma concentrations in humans
are 40 µM and 8 µM.
The importance of cysteine is related to the
presence of a sulphur-containing thiol group
in its side chain (a thiol is a compound that
contains the functional group composed of a
sulphur atom and a hydrogen atom). Thus,
cysteine plays a key role in the regulation of
cellular redox status. Cysteine is also the
rate-limiting amino acid in glutathione
synthesis, which is a major cellular defence
factor against reactive molecules in the body
(Shoveller et al., 2005).
4.4.1 Interaction of acetaldehyde and
cysteine
In this section, a review of the interaction of
acetaldehyde and cysteine is given. The
MEDLINE search was executed as follows:
Cysteine AND acetaldehyde [34].
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From the resulting 35 studies, 14 were
included, as they covered the interaction of
acetaldehyde and cysteine in vitro or in vivo.
Eight of these were experimental animal
studies, five in vitro studies and one a
human study. In the human study, plasma
free glutathione and cysteine levels were
measured after ethanol administration. In
addition, two studies were manually selected
(Susilo et al., 1989; Wlodek et al., 1993).
None of the studies dealt with local
acetaldehyde reduction or binding of
acetaldehyde with cysteine in the human
gastrointestinal tract. Studies dealing with
systemic augmentation of glutathione with
cysteine, peptide-bound cysteine or the
effect of cysteine on ethanol-metabolizing
enzymes were excluded.
For many decades, thiols have been known
to be effective protective agents against
certain harmful substances. A “Thiol
defence” hypothesis was presented to
explain the removal of free cysteine from
the bronchial cells by the inhalation of
compounds in cigarette smoke.
Acetaldehyde was stated to be the main
component responsible for thiol removal.
Consequently, acetaldehyde was able to
react with cysteine according to the
following equation:
acetaldehyde        +          cysteine ↔     2-methyl-thiazolidine-          +      water
                                                                              4-carboxylic acid (MTCA)
Experimental studies from the 1960s already
showed a significant reduction of tobacco-
smoke derived acetaldehyde in water
solution supplemented with cysteine
(Braven et al., 1967; Fenner and Braven,
1968). Many studies have since confirmed
the ability of L-cysteine to form an adduct
with acetaldehyde by the above-mentioned
non-enzymatic condensation reaction at a
physiological pH and temperature,
subsequently forming 2-methyl-thiazolidine-
carboxylic acid (MTCA) (Macdonald et al.,
1977; Susilo et al., 1989; Ungar et al., 1973;
Wlodek et al., 1993). In vitro, increasing
amounts of cysteine progressively decreased
the detectable content of acetaldehyde.
Moreover, there was no release of
acetaldehyde, i.e. the reaction was not
reversible in a 20 min incubation
(Cederbaum and Rubin, 1976b). Based on
this reaction, cysteine was found to protect
the mitochondria from acetaldehyde-induced
injury in vitro (Cederbaum and Rubin,
1976a). Experimental studies in animals
have shown the protective effect of L-
cysteine against acetaldehyde also in vivo
(O´Neill and Rahwan, 1976). High oral dose










excellent protection (80% survivors) against
oral intubation of LD90 dose (18 mM/kg and
0.2 mM/kg) of acetaldehyde or acrolein,
respectively. However, the best protection
and 100% survival was offered by a mixture
of L-cysteine, thiamin and l-ascorbic acid
(Sprince et al., 1975; Sprince, 1985).
Intraperitoneal injection of L-cysteine (300
mg/kg) resulted in faster ethanol oxidation
and reduced blood, brain and liver
acetaldehyde concentrations during ethanol
metabolism in mice (Tsukamoto et al.,
1990). The reduction of liver acetaldehyde
levels by L-cysteine was confirmed by a
study in rats (Ryle et al., 1987).
Acetaldehyde-binding capacity of L-
cysteine has also been shown in a human
blood medium, in which acetaldehyde was
reduced to 47% by L-cysteine in vitro.
Interactions of acetaldehyde and sulphydryls
have been elucidated in only one human
study. Plasma free glutathione and cysteine
levels were measured following
administration of 0.2 g/kg of body weight of
ethanol in healthy volunteers and in
alcoholics on disulfiram. In patients on
disulfiram, but not in healthy controls,
plasma cysteine decreased significantly,
which was correlated with the rise in
acetaldehyde, suggesting the binding of L-
cysteine to acetaldehyde (Burgunder et al.,
1988).
4.4.2 Problems related to the in vivo use of
cysteine
Many researchers have examined the
antioxidant effect of parenteral L-cysteine
supplementation. Most of these studies have
failed due to certain problems in the
administration of cysteine. These studies
were not systematically reviewed since this
thesis is based on the local binding of
acetaldehyde in the saliva by administrating
a small dose of L-cysteine perorally.
However, some studies will be discussed in
the next paragraph to elucidate the
differences between systemic and locally
administered L-cysteine. The stability and
metabolism of the condensation product of
L-cysteine and acetaldehyde  thiazolidine-
carboxylic acid  will also be discussed.
The administration of free cysteine has been
suggested to be toxic. Oral, subcutaneous or
intraperitoneal administration of cysteine
has been reported to induce neurological
damage in experimental animals. An excess
of L-cysteine may act as a neuronal
excitotoxin in sites that lack the blood-brain
barrier or in developing animals with
immature blood-brain barriers (Janaky et al.,
2000). These effects have come about with
doses of 1-2 g/kg of body weight of L-
cysteine (Meister, 1989). In other words, the
respective harmful dose in a 70 kg human
would be 80 g, which is several 100-fold
higher than the maximum dose described in
our studies. In humans, cysteine-
supplemented diets (6.5 mg/ kg/day) have
been used without investigating of possible
toxicity (Raguso et al., 2000).
The second problem with systemic
administration of cysteine is the reactivity of
this amino acid. In other words, it is unlikely
that free, effective cysteine will reach the
desired site of action through systemic
delivery. Studies have in fact shown that
systemic administration of cysteine itself is
ineffective (Anderson and Meister, 1987).
Thus, different kinds of cysteine prodrugs
have been developed to improve delivery
(Gwilt et al., 1998). However, these drugs
are not likely to be effective in binding
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acetaldehyde locally since they need
metabolic alteration to be as active as
cysteine.
As mentioned earlier, MTCA is formed
from the reaction of acetaldehyde with
cysteine. The formation and actions of
MTCA in vivo are largely unknown.
However, MTCA has been proposed to be
also endogenously formed in the human
body when L-cysteine inactivates
endogenous or exogenous acetaldehyde. The
further metabolism of the formed MTCA in
humans is unclear. Some in vitro studies
have shown that MTCA is decomposed in
hours, yielding 50-55% of the original
concentration of acetaldehyde (Speisky et
al., 1985). It has also been suggested that
methyl-djenkolic acid (MDA) is formed
from the ring opening of MTCA. MDA was
demonstrated in hydrolysates of mammalian
tissue (Wlodek et al., 1993). The most
probable explanation in vivo is endogenous
nitrosation of MTCA, forming N-
nitrosothiazolidine 4-carboxylic acid
(NMTCA). Endogenous nitrosation of
MTCA to NMTCA may have prevented
detection of MTCA in the urine of rats
simultaneously given cysteine and ethanol,
or synthetic MTCA (Kallama and
Hemminki, 1983; Nagasawa et al., 1975).
NMTCA is easily formed in vitro when L-
cysteine, acetaldehyde and nitrite are
incubated together. When NMTCA is
administered to rats, more than 90% of this
compound is recovered unchanged from the
urine and faeces. Furthermore, NMTCA is
also detected in the urine of human
volunteers without exogenous
administration. Cigarette smokers have been
shown to excrete higher levels of NMTCA
than non-smokers. The detected NMTCA is
suggested to develop when acetaldehyde
from cigarette smoke reacts with
endogenous L-cysteine to form MTCA,
which undergoes nitrosation and yields
NMTCA (Ohshima and Bartsch, 1984). It is
likely that the carcinogenic potential of
NMTCA is very low, if present at all, since
the compound is not metabolically
converted in experimental animals.
Furthermore, toxic or other adverse
biological effects of MTCA and NMTCA
have not been reported.  However, further
studies are warranted to elucidate the final
biological significance of these compounds
since the excretion of nitrosated
thiazolidines in humans has been established
(Ohshima and Bartsch, 1984).
In conclusion, there is solid evidence that
cysteine is able to bind to acetaldehyde and
thus reducing acetaldehyde in vitro and in
vivo. Furthermore, data strongly suggest that
cysteine should be administered locally in
order to be effective in acetaldehyde
elimination. The thiazolidine derivative
formed during condensation of cysteine and
acetaldehyde probably undergoes nitrosation
in vivo, forming NMTCA. This substance is
detected in vivo from human urine,
especially from smokers, indicating
endogenous deactivation of acetaldehyde by
cysteine.
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AIMS OF THE STUDY
Alcohol consumption and tobacco
smoking are the primary risk factors for
oral, pharyngeal, laryngeal and
oesophageal cancers. Furthermore, their
combined use has a synergistic effect on
cancer risk. The mechanisms behind the
development of cancer associated with
alcohol and smoking remain obscure.
Recent epidemiological findings provide
strong evidence for the carcinogenicity of
acetaldehyde in humans. Carcinogenic
acetaldehyde is the first metabolic product
of ethanol and also a major constituent of
tobacco smoke. Thus, determining
acetaldehyde production and exposure in
the human upper digestive tract during
alcohol consumption and smoking is
important. As acetaldehyde is one of the
primary carcinogens, a reduction in local
acetaldehyde concentration might offer
substantial benefits. The objective here
was to investigate the use of L-cysteine in
the elimination of acetaldehyde from the
saliva in order to reduce the local exposure
of the human upper digestive tract to this
carcinogen.
Specific aims were as follows:
1) To elucidate acetaldehyde production
and ethanol oxidation capability of human
intestinal strains of Escherichia coli in the
different atmospheric conditions
prevailing in the digestive tract.
2) To examine the combined effect of
alcohol consumption and tobacco smoking
on in vivo acetaldehyde levels of saliva.
3) To investigate the ability of L-cysteine,
which was slowly released from a
specially designed drug formulation, to
reduce salivary acetaldehyde levels after
the ingestion of alcohol.
4) To examine the ability of a L-cysteine-
containing lozenge to bind acetaldehyde
from saliva during smoking.
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MATERIALS AND METHODS
1 ACETALDEHYDE PRODUCTION AND ETHANOL OXIDATION BY
ESCHERICHIA COLI (I)
Culture conditions and bacteria studied
Bacterial strains (Table 1), with “high” (IH
50546) and “low” (IH 50817) expression of
ADH  activity were grown on Brucella agar
plates supplemented with 5% defibrinated
sheep blood in aerobic (i.e. air),
microaerobic (6%, O2) and anaerobic
conditions at 35°C for 48 h.
Table 1. Bacteria investigated in Study I.
ADH
       ______________________________________
  Name                            Strain           Isolated from        Activity  (nmol/min /mg)          Km (mM)
Escherichia coli            IH 50546        Stool                      354±28                                 2.78±0.8
         IH 50817           Stool                       7.5±3.7                            NM
NM= not measurable
ADH determinations
Bacterial cells were harvested from the
plates after 8, 12, 22 and 48 hours of
incubation to obtain the bacterial mass. For
ADH determination 22-hours samples were
used. The harvested cells were washed three
times in 100 mM potassium phosphate and
adjusted to a turbidity of 4 on the McFarland
scale. An aliquot of this suspension was then
sonicated in an ice path. To obtain the
cytosol, the sonicate was centrifuged at
100 000g at 5°C for 60 min. Cytosolic ADH
activity was then determined
spectrophotometrically by measuring, after
addition of ethanol (final concentration 25
mM), the reduction of NAD at 25°C in 100
mM glycine buffer (pH 9.6). Cytosolic
protein concentration was determined by the
Bio-Rad method (Bio-Rad protein assay;
Hercules, Ca, USA), and the ADH activity
was calculated as nanomoles of reduced
NADH produced by 1 mg protein/min.
Determination of ethanol consumption and
acetaldehyde production
The bacteria were grown on agar plates with
0 mM (control), and 51±2 mM (aerobic) or
59±1 mM (microaerobic) (ethanol plates)
ethanol concentrations. Samples of culture
media as agar blocks were excised with a
scalpel and collected in a headspace sample
vial after 0, 8, 12, 22 and 48 h of incubation.
To test the volatile losses of acetaldehyde,
some agar plates were sealed with parafilm,
and no significant losses were detected. To
avoid artifactual acetaldehyde formation, the
vials were immediately closed and kept
frozen at -20°C until analysed. Ethanol and
acetaldehyde concentrations of the samples
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were analyzed by headspace gas
chromatography as described in section 1.5.
The ethanol consumption rate from the agar
plate was obtained by dividing the initial
supplemented dose by the estimated time to
reach a zero concentration of ethanol in the
agar. Non-inoculated agar plates, incubated
in parallel with the test plates, were used as
controls, and the values thus obtained were
subtracted from the ethanol levels of the
samples inoculated with bacteria. The non-
inoculated agar plates were also used for the
detection of artifactual acetaldehyde.
Anaerobic and microaerobic conditions
were achieved by using the anoxomat
system (Mart, Lihtenvoore, The
Netherlands), to evacuate and replace the
normal atmospheric air with an anaerobic
gas mixture (80% N2, 10% H2, and 10%
CO2). The microarobic atmosphere
contained 6% O2. The results of the ethanol
consumption, fermentation and acetaldehyde
production are based on two or more
separate experiments.
2 EFFECT OF ALCOHOL DRINKING AND SMOKING ON SALIVARY
ACETALDEHYDE (II)
Subjects and study design
Thirteen healthy volunteers (10 males, 3
females) took part in the study. Six of the
volunteers were non-smokers, mean age
28.8±1 (range 26-35) years and seven
regular cigarette smokers, mean age 39.5±3
(range 26-61) years. Information about the
smoking status, alcohol consumption and
nutritional habits was obtained by self-
reported questionnaire. All volunteers were
moderate alcohol consumers, with a weekly
average consumption of 70 g or less of
alcohol, and all were devoid of any clinical
signs of poor oral hygiene. The average
cigarette consumption among smokers was
18.5 ± 2.1 (range 15-30), and all had a
smoking history of more than ten years. All
of the volunteers were on normal Western
diet, and none were vegetarians. The
volunteers were divided into two separate
groups: smokers and non-smokers. Two
repeated measurements (study dates
separated by at least a three-day interval)
were done with the smokers, and the non-
smokers were used as controls. Exclusion
criteria were as follows: treatment with
antibiotics or oral antiseptic in the past
month, recent food or fluid intake and
smoking or tooth brushing during the
previous 30 min. All participants were
requested to refrain from alcohol use for at
least 24 h before the study.
Determination of the effect of ethanol
ingestion on in vivo salivary acetaldehyde
in smokers and non-smokers
To measure the salivary acetaldehyde
derived solely from ethanol, both parallel
groups (smokers and non-smokers) ingested
0.8 g ethanol/kg body weight in a
standardized 10% v/v solution of absolute
ethanol in distilled water/orange juice
(50%/50%) within 30 min after baseline
saliva collection. To remove local ethanol,
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the subjects rinsed their mouths three times
with water, and saliva samples were then
taken every 20 min for 160 min.
Determination of the effect of combined
ethanol ingestion and tobacco smoking on
in vivo salivary acetaldehyde in smokers
To measure the salivary acetaldehyde
derived from the combined and
simultaneous use of ethanol and tobacco, the
above-mentioned procedure was repeated in
smokers. Smokers then smoked one
cigarette every 20 min, and saliva samples
were collected every 10 min for 160 min.
Determination of the effect of smoking on
in vivo salivary acetaldehyde in smokers
To measure the salivary acetaldehyde
derived solely from smoking, the smokers
smoked one cigarette (without ethanol
ingestion) within 5 min after measuring the
base level of salivary acetaldehyde. Salivary
samples were then collected every 5 min for
15 min.
Collection and analysis of salivary
acetaldehyde
To obtain saliva samples, volunteers were
told not to swallow the secreted saliva but to
retain it in their mouth. After 5 min, the
saliva was collected into a sample tube and
450 µl of saliva was immediately transferred
into a vial containing 50 µl of PCA.
Acetaldehyde and ethanol levels were
analysed by headspace gas chromatography
as described in section 1.5. Each in vivo
measurement was done in duplicate.
3 BINDING OF SALIVARY ACETALDEHYDE BY L-CYSTEINE DURING
ALCOHOL METABOLISM (III)
Subjects
Nine healthy male volunteers, mean age
(±SEM) 27 ± 1 years, took part in the study.
All of them were moderate alcohol
consumers, with a weekly average
consumption of 70 g or less of ethanol, and
all were devoid of any clinical signs of poor
oral hygiene. One of the subjects was a light
smoker (less than 7 cigarettes per day).
Exclusion criteria were as follows: treatment
with antibiotics or oral antiseptic in the past
month, recent food or fluid intake and
smoking or tooth brushing during the
previous 90 min. All participants were told
to refrain ingesting ethanol for at least 36
hours before the study.
Study design
A paired, placebo-controlled design in
which each subject served as his own
control was used. The two study days were
separated by at least 48 h. A commercially
available paraffin wax chewing gum (Orion
Diagnostics, Espoo, Finland) was used to
stimulate the production of saliva, and the
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volunteers were instructed to chew at all
sites of the jaw to yield a representative
sample. After baseline saliva collection (2
ml within 2 minutes), each volunteer
fastened a placebo- or L-cysteine-containing
tablet under their upper lip at the beginning
of each measurement and the baseline saliva
collection was repeated. After the second
baseline saliva collection, each volunteer
ingested 0.8 g of ethanol/kg body weight in
a standardized 10% v/v solution of absolute
ethanol in distilled water within 20 min. To
remove local ethanol, the subjects rinsed
their mouths with water, and saliva samples
were then collected at 20- min intervals for
320 min.
L-cysteine-/ placebo drug formulation
The placebo tablet was composed of 130 mg
of hydroxypropyl methylcellulose (HPMC)
(Methocel K4M Premium EP, The Dow
Chemical Company, USA), 6.9 mg of
carbomer (Carbopol 971P NF, BF Goodrich
Company, USA) and 1.4 mg of magnesium
stearate (Ph.Eur.). The composition of the L-
cysteine tablet was exactly the same, except
that 130 mg of HPMC was reduced to 30 mg
and replaced with 100 mg of L-cysteine
(Sigma Chemical Co., USA). HPMC and
carbomer enables the binding of the tablet to
the gingiva and the slow release of L-
cysteine.
In vivo salivary acetaldehyde production
To measure in vivo salivary acetaldehyde
levels, 450 µl of saliva was immediately
transferred into a vial that contained 50 µl of
6 mol/l PCA. Acetaldehyde and ethanol
levels were analysed by headspace gas
chromatography as described in paragraph
1.5. Each measurement was done in
duplicate. In order to minimise the effects of
artifactual acetaldehyde formation the
baseline values were subtracted from the
acetaldehyde levels measured during the
experiment.
4 BINDING OF SALIVARY ACETALDEHYDE BY L-CYSTEINE DURING
SMOKING (IV)
Subjects
Seven healthy volunteers (5 males, 2
females), mean age 28±1.9 (range 21-37)
years, took part in the study. Information
about the smoking status, alcohol
consumption and possible medications was
obtained by a self-administered
questionnaire. Five of the volunteers were
active smokers (more than 10 cigarettes/day,
>5 years) and two were habitual smokers
(less than 10 cigarettes/week). All of the
volunteers were moderate alcohol
consumers, with a weekly average
consumption of 70 g or less, and all were
devoid of any clinical signs of poor oral
hygiene. Exclusion criteria were as follows:
treatment with antibiotics in the past month,
use of antiseptic mouthwash in the past
week and smoking during the previous 60
min. Participants were told to refrain from




A placebo-controlled single-blinded study
design, in which each subject served as
his/her own control, was used. All
volunteers smoked a total of five cigarettes
(Marlboro, Philip Morris Finland Oy,
Helsinki), with at least a 30 min wash-out
period between, to test the placebo tablet
and four tablets with different
concentrations of L-cysteine. Before
smoking, volunteers started to suck in
randomized order, single-blinded tablets,
containing 0 (placebo), 1.25, 2.5, 5 or 10 mg
of L-cysteine. The tablets were designed to
dissolve during cigarette smoking. In
addition to L-cysteine (Fluka Biochemika,
Bucks, Switzerland) the tablets contained
725 mg (in placebo tablet 745 mg) of
Mannitole (Parteck M 200, Merck KgaA,
Germany), 20 mg blackcurrant-flavour
(Quest International, Naarden, the
Netherlands) and 2% magnesium stearate
(Ph.Eur., Merck, Darmstadt, Germany).
To measure in vivo levels of  acetaldehyde
during smoking, salivary samples were
collected from each volunteer during
smoking periods with each tablet:  i) before
smoking to measure the baseline (-5 to 0
min), ii) immediately after smoking (0-5
min collection), iii) 5 min after smoking (5-
10 min collection) and iv) 10 min after
smoking (10-15 min collection). To obtain
the saliva samples, volunteers were told not
to swallow the secreted saliva but to retain it
in their mouths. After the 5-min collection
period, saliva was spit into a sample tube,
and 500 µl were transferred into a vial and
analysed immediately. Acetaldehyde levels
were analysed by headspace gas
chromatography as described in section 1.5.
Each in vivo measurement was done in
duplicate.
To determine how rapidly the salivary
acetaldehyde increases again after the tablet
had dissolved, three volunteers smoked one
cigar (Hofnar, Swedish Match Cigars B.V.
Holland) in order to make the smoking time
longer than 6.3 min (dissolving time of the
tablet). Just before smoking, they started to
suck tablet containing 5 mg of L-cysteine.
Salivary samples were then taken at 3-min
intervals for 20 min. The sample procedure
was the same as described above.
5 MEASUREMENT OF ACETALDEHYDE AND ETHANOL BY GAS
CHROMATOGRAPH
Acetaldehyde (Studies I-IV) and ethanol
(Studies I- III) levels were analysed by using
headspace gas chromatography (Perkin
Elmer, Norwalk, CT, USA)  in which the
vials were heated to a temperature of 37°C,
as reported earlier (Jokelainen et al., 1994).
The conditions for the analysis were as
follows: Column 60/80 Carbopack B/5%
Carbowax 20 M, 2 m x 3mm, Supelco, Inc.,
Bellefonte, PA, USA); oven temperature,
85°C; transfer line and detector temperature
200°C; carrier gas flow rate (N2) 20ml/min.
Artifactual formation of acetaldehyde from
ethanol during protein precipitation was
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measured as follows: PCA was added
simultaneously with ethanol into additional
vials which were not incubated (I, II). The
acetaldehyde concentrations of these control
samples were subtracted from the
acetaldehyde values obtained from the
samples after the incubation period. The
interference of artifactual acetaldehyde
formation in Study III was eliminated as the
study subjects served as their own controls.
In the study no IV, parallel salivary samples
without the effect of smoking were used to
control acetaldehyde formation in vitro.
These values were subtracted from the in
vivo concentrations.
6 STATISTICAL ANALYSIS
All values are expressed as means ±
standard error of the mean (SEM) (I-III) or
means ± SD (IV). The areas under the
acetaldehyde concentration-time curves
(AUC) were determined by using NCSS
2000 statistical software (239 North 1000
East, Kaysville, UT, USA) (II, III).
Statistical differences between the study
groups were analysed by Mann-Whitney
rank-sum test (I, III, IV) or Wilcoxon
signed-rank test (II). P values of less than
0.05 were regarded as significant.
7 ETHICAL CONSIDERATIONS
Study protocols dealing with patients or
volunteers (II-IV) were approved by the
Ethical Committee of the Helsinki
University Central Hospital and by the
Finnish National Agency for Medicines (II,




1 ADH-DEPENDENT ACETALDEHYDE FORMATION OF ESCHERICHIA COLI
IN DIFFERENT OXYGEN TENSIONS (I)
ADH-mediated ethanol oxidation and
acetaldehyde production were detected in
both aerobic and microaerobic conditions in
vitro. The human intestinal strain of E. coli
(IH 50546), which possessed high ADH
activity, was able to produce significant
concentrations of acetaldehyde compared
with the other E. coli strain with low ADH
activity (IH 50817). Some ethanol and
acetaldehyde was also produced by
fermentation in anaerobic conditions.
In aerobic and microaerobic (6% of oxygen)
conditions, the ethanol consumption rate of
the high ADH activity possessing E. coli
was markedly higher than that of the low
ADH activity strain, as expected. The
ethanol consumption rates in aerobic and
microaerobic conditions are shown in Figure
1. The ethanol consumption rate of IH
50546 (high ADH activity strain) was
associated with almost linear acetaldehyde
production. The acetaldehyde levels
produced in aerobic and microaerobic
conditions reached several hundreds of µM
concentrations in vitro. The acetaldehyde
production of the two E. coli strains in
aerobic conditions is presented in Figure 2.
Under anaerobic conditions, when oxygen
was unavailable, ethanol was not consumed,
as expected. However, both strains were
capable of alcoholic fermentation, and up to
5 mM concentration of ethanol was
produced. This was associated with
acetaldehyde production of 73.7±14.5 µM
with IH 50546 and 49.4±3.4 µM with IH
50817.
Fig. 1. Ethanol consumption rates (mean±SEM) of
Escherichia coli IH 50817 and IH 50546 under
aerobic and microaerobic conditions. * p<0.05.
(reproduced with permission).
Fig. 2. Acetaldehyde concentrations (mean±SEM) in
agar plates supplemented with ethanol and cultured
under aerobic conditions with Escherichia coli IH















































2 SYNERGISTIC EFFECT OF ALCOHOL DRINKING AND SMOKING ON
ACETALDEHYDE CONCENTRATION IN SALIVA (II)
Smokers without concomitant smoking
during ethanol challenge had two times
higher in vivo salivary acetaldehyde
concentration than non-smokers. Moreover,
with active smoking during the ethanol
challenge, the salivary acetaldehyde
exposure in smokers further increased, being
sevenfold that of non-smokers.
The mean in vivo salivary acetaldehyde in
smokers, even without smoking, after a
moderate ethanol dose (0.8g/kg of body
weight) was approximately two times higher
than in non-smokers throughout the follow-
up period of 160 min. The area under the
curve (AUC) of salivary acetaldehyde in
smokers and non-smokers was 114±12 and
54±9 µM x hr, respectively (p=0.002)(Fig.
3).
During active smoking, the in vivo salivary
acetaldehyde was increased 10-fold over
levels derived from ethanol ingestion alone
in smokers. The AUC of salivary
acetaldehyde in smokers with concomitant
smoking and ethanol challenge was seven
times higher than in non-smokers with
ethanol challenge alone (370±12 and 54±9
µM x h, respectively (p<0.001) (Fig. 4).
The effect of smoking alone on in vivo
salivary acetaldehyde level is shown in
Figure 5. The acetaldehyde level is
immediately increased to several hundred
micromolars when smoking starts, declining
rapidly after cessation of smoking.
Fig. 3. In vivo salivary acetaldehyde levels
(mean±SEM) after ethanol ingestion in smokers
(without concomitant smoking) and in non-smokers.
(Reproduced with permission).
Fig. 4. In vivo salivary acetaldehyde after ethanol
ingestion in smokers (with concomitant smoking) and
in non-smokers. (reproduced with permission).
Fig 5. Salivary acetaldehyde in smokers after
smoking one cigarette. (reproduced with permission).
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3 ABILITY OF SLOW-RELEASING L-CYSTEINE TABLET TO BIND
ACETALDEHYDE IN SALIVA DURING ALCOHOL METABOLISM (III)
The mean in vivo salivary acetaldehyde
levels after ethanol ingestion were two to
three times lower with the L-cysteine tablet
than with the placebo. L-cysteine reduced
the exposure of the oral cavity, pharynx and
oesophagus to the carcinogenic
acetaldehyde by 59 ± 8%. Thus, the L-
cysteine tablet enables the binding of
continuously formed acetaldehyde in saliva.
The AUC of salivary acetaldehyde with the
L-cysteine tablet was 54 ± 11 µM x h and
with the placebo 162 ±34 µM x h. The in
vivo salivary acetaldehyde levels with the
cysteine and placebo tablets are shown in
Figure 6.
The corresponding salivary ethanol levels
were equal in placebo and L-cysteine
experiments throughout the follow-up.
Fig. 6. In vivo acetaldehyde levels (mean±SEM) in
saliva of volunteers with placebo or L-cysteine-
containing buccal drug formulation after a dose of
alcohol. Differences between concentrations are
significant at all time points from 20 min to 320 min
(p≤0.001). (reproduced with permission).
4 ELIMINATION OF ACETALDEHYDE FROM SALIVA BY L-CYSTEINE
SUCKING TABLET DURING SMOKING (IV)
All of the tested tablets with different L-
cysteine concentrations significantly
reduced or totally eliminated the in vivo
salivary acetaldehyde derived from
smoking. However, the minimal L-
cysteine concentration that was able to
totally eliminate acetaldehyde from the
saliva was 5 mg. Accordingly, the salivary
acetaldehyde levels with placebo (0 mg) or
1.25, 2.5, 5, 10 mg of L-cysteine
immediately after smoking were 228±15,
85±42, 9±7, 0.09±0.2 and 0±0 µM,
respectively (Fig. 7).
The mean dissolving time of the lozenge
was 6.3±0.8 min i.e. longer than one
cigarette smoking period. After the tablet
had dissolved, salivary acetaldehyde
increased within 3 min to levels
comparable with the placebo (Fig. 8).
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Fig. 7. Salivary acetaldehyde levels immediately
after tobacco smoking with placebo- or L-cysteine-
containing tablet. * p=0.007, ** p<0.001.
(reproduced with permission).
Fig. 8. Salivary acetaldehyde concentration in vivo
during cigar smoking with a tablet containing 5 mg
of L-cysteine. (reproduced with permission)
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1 EXPERIMENTAL EVIDENCE OF MICROBIAL ACETALDEHYDE
PRODUCTION UNDER DIFFERENT ATMOSPHERIC CONDITIONS
PREVAILING IN THE DIGESTIVE TRACT
The gastrointestinal microbiota is exposed to
significant ethanol concentrations during
normal alcohol metabolism. Thus,
microbially mediated ethanol oxidation, in
which ethanol is oxidized to acetaldehyde,
may lead to marked local acetaldehyde
production in the digestive tract. Several
studies have shown that human colonic
contents are capable of oxidizing ethanol to
acetaldehyde both in vitro and in vivo. This
reaction is catalysed primarily by microbial
alcohol dehydrogenase (ADH). Our results
also show that ADH activity-expressing E.
coli is capable of considerable ethanol
oxidation and acetaldehyde production at
ethanol concentrations in the gut comparable
to those during normal drinking.
Acetaldehyde production was strong in both
aerobic and microaerobic conditions, but
significant levels of endogenous
acetaldehyde were also produced in
anaerobic conditions.
The human microbiota consists of several
hundred bacterial species and approximately
1014 individual bacteria. Thus, the
microbiota can be considered a
metabolically active organ. Bacterial count
varies throughout the gastrointestinal tract,
with for example local differences between
the luminal and mucosal microbiota. In the
colonic lumen, the oxygen tension is so low
that for the most part only anaerobes can
flourish. However, at the mucosal surface,
oxygen diffusion from the mucosa is
sufficient to maintain significant 02 pressure,
capable of inhibiting the growth of strict
anaerobes. Experimental studies have shown
that pO2 of intestinal mucosa is similar to
that of venous blood. Accordingly, aerobes
on the colonic mucosa are as numerous as or
even more numerous than anaerobes. Thus,
atmospheric conditions throughout the
digestive tract may influence the
composition and metabolism of the
microbiota.
As presented in the results, under anaerobic
conditions, both bacterial strains (“high” and
“low” activity E. coli) carried out alcohol
fermentation, producing ethanol via
acetaldehyde, which both were produced at
measurable levels. However, under aerobic
and more importantly  microaerobic
conditions prevailing near the mucosa, only
the high ADH activity E. coli were able to
produce significant amounts of
acetaldehyde. Thus, ADH-mediated ethanol
oxidation is possible under different
atmospheric conditions of the gut with
varying oxygen tensions. Studies presented
in this thesis were carried out with E. coli,
but the results are probably also applicable
to other microbes possessing ADH activity
and to the entire digestive tract, from the
oral cavity to the large intestine.
However, as it is known that aerobic and
facultative anaerobic microbiota in the
human digestive tract may contain various
types of ADH enzymes with low or high
activities and with different Km values,
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differences may account for individual
acetaldehyde levels in the saliva, gastric
juice and the contents of the large intestine.
Furthermore, since significant ethanol
fermentation occurs under anaerobic
conditions in different parts of the digestive
tract, this endogenous ethanol can also be
oxidized to acetaldehyde under the
microaerobic conditions prevailing close to
mucosal surfaces. Accordingly, significant
levels of endogenous acetaldehyde are
detected at least in the large intestine even
without alcohol consumption (Salaspuro V
et al., unpublished data).
In conclusion, our results suggest the
existence of a complex and versatile
microbial pathway for the production of











Fig. 9. Different pathways for microbial production of endogenous and exogenous acetaldehyde in the
digestive tract from glucose or ingested ethanol under aerobic or/and anaerobic conditions.
2 MULTIPLICATIVE EXPOSURE TO CARCINOGENIC ACETALDEHYDE
BEHIND THE SYNERGISTIC EFFECT OF ALCOHOL AND TOBACCO ON
CANCER RISK
Tobacco smoking and alcohol consumption
are the main risk factors for upper digestive
tract cancers. When combined, alcohol and
tobacco have a multiplicative effect on
cancer risk, suggesting a synergistic tumour-
promoting effect. The mechanism has thus
far been poorly understood. However, as
carcinogenic acetaldehyde is a major
constituent of tobacco smoke that is
dissolved in saliva and is also locally
produced from ethanol in the upper
digestive tract, excessive exposure to this
carcinogenic substance might be a potential
explanation of the markedly increased
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cancer risk associated with combined
smoking and drinking.
Smokers, even without acute smoking, were
shown to have two times higher salivary
acetaldehyde concentration than non-
smokers during ethanol challenge. This
implies that smokers have changes in their
oral microbiota, resulting in an increased
capacity to produce acetaldehyde from
ethanol, as previously also shown in vitro
(Homann et al., 2000). Moreover evidence
exists of the inhibition of mucosal ALDH
enzyme mediated by toxic tobacco smoke,
which could result in less efficient
acetaldehyde removal and higher
acetaldehyde concentration in the
aerodigestive tract of chronic smokers
(Helander and Curvall, 1991).
Our second finding was that acetaldehyde is
easily and rapidly dissolved from tobacco
smoke into the saliva during smoking.
Accordingly, smoking alone increases in
vivo salivary acetaldehyde to over 250 µM
during every smoking period. However,
large interindividual variations were present
in salivary acetaldehyde, ranging from 100
µM to 400 µM. The total exposure of
smokers to acetaldehyde is large influenced
by smoking frequency and whether or not
tobacco smoke is inhaled. Nevertheless,
these in vivo acetaldehyde levels have been
shown to be mutagenic. Due to the
deposition of acetaldehyde into the
aerodigestive tract, the carcinogenic
acetaldehyde also reaches the oesophagus
and stomach via normal wash-out of saliva.
This provides a sound explanation for the
increased oesophageal and stomach cancers
risks observed in smokers and alcohol
drinkers.
This multifold increase in salivary
acetaldehyde concentration may have a
pronounced effect on the upper digestive
tract cancer risk of heavy drinkers, who are
often also heavy smokers. The combined use
of alcohol and tobacco dramatically
increased salivary acetaldehyde.
Consequently, salivary acetaldehyde levels
after an ethanol dose were seven times
higher in smokers with active smoking
(every 20 min) than in non-smokers.
Although, salivary acetaldehyde declined
rapidly, the basal level in smokers was still
two times higher than in non-smoking
controls during ethanol challenge.
In conclusion, continuous acetaldehyde
exposure in smokers during alcohol
consumption is double that of non-smokers.
Furthermore, active smoking induces
dramatic but momentary acetaldehyde peaks
in saliva. With simultaneous smoking and
drinking, there is a markedly increased
exposure to carcinogenic acetaldehyde,
which may explain the synergistic and
multiplicative risk effect of alcohol and
smoking on upper digestive tract
carcinogenesis.
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3 REDUCING EXPOSURE OF THE UPPER DIGESTIVE TRACT TO
CARCINOGENIC ACETALDEHYDE BY L-CYSTEINE AFTER ALCOHOL
CONSUMPTION
A plausible explanation for the increased
upper digestive tract cancer risk in
alcoholics and heavy alcohol consumers is
the increased local acetaldehyde
concentration in saliva, which, via
swallowing, is distributed to all parts of the
upper digestive tract. This theory is strongly
supported by epidemiological studies on
ALDH2-deficient Asian alcohol consumers,
who possess abnormally high cancer risk
associated with high local acetaldehyde
levels in saliva after ingesting alcohol. The
theory is also supported at least in part by
studies on Caucasian alcoholics and heavy
drinkers who are homozygous for the fast-
alcohol metabolizing (ADH1C*1) enzyme,
resulting in abnormally high salivary
acetaldehyde concentration after alcohol
consumption and also in an increased risk of
alcohol-related upper digestive tract cancers.
In theory, the harmful effects of reactive
acetaldehyde could be prevented by binding
it to L-cysteine. Thiol compounds, such as
cysteine, can bind aldehydes in vitro and
protect against acetaldehyde toxicity in vivo.
Cysteine is able to inactivate the reactivity
of acetaldehyde by non-enzymatic binding,
forming a more stable compound, 2-
methylthiazolidine-4-carboxylic acid.
Cysteine is a semi-essential amino acid that
is present after protein digestion also in the
normal diet. The protective role of L-
cysteine in humans has thus far been thought
to be linked to its systemic effects via
intracellular glutathione, as cysteine is the
rate-limiting amino acid in the synthesis of
glutathione. The hypothesis presented here,
however, is related to the local use of L-
cysteine to bind acetaldehyde in situ,
without its systemic delivery. This is
associated with several benefits including,
(i) cysteine would not have to be absorbed
from the gut, (ii) formed acetaldehyde is
directly and immediately bound at the site of
formation and (iii) the total amount of
delivered cysteine could be kept low.
To bind continuously formed acetaldehyde
during ethanol oxidation in the oral cavity, a
special buccal drug formulation was
developed. This tablet slowly releases intact
L-cysteine, which enables continuous and
direct local binding of reactive acetaldehyde.
Consequently, up to two-thirds of
carcinogenic acetaldehyde can be removed
from saliva after alcohol intake. This drug
formulation could potentially be used to
prevent the toxic effects of acetaldehyde
during alcohol consumption. This could be
of special benefit to individuals with
increased acetaldehyde exposure during
drinking, e.g. ALDH2-deficient Asians and
subjects who are homozygous for the
ADH1C1 enzyme. Since the L-cysteine
tablet was found to be effective and safe in
in vivo use, these findings warrant further
clinical trials.
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4 REDUCING EXPOSURE TO CARCINOGENIC ACETALDEHYDE BY L-
CYSTEINE DURING SMOKING
As stated in the literature review,
acetaldehyde is one of the major toxic
components of tobacco smoke.
Acetaldehyde is easily dissolved from the
mainstream smoke into saliva and further to
the entire aerodigestive tract of smokers.
This could be one of the major mechanisms
by which acetaldehyde, and probably also
some other carcinogens of tobacco smoke
might mediate toxic and carcinogenic
effects. L-cysteine released slowly from the
buccal tablet can effectively bind ethanol-
derived salivary acetaldehyde. Moreover,
orally administered L-cysteine can totally
eliminate the tobacco smoke-derived
acetaldehyde from saliva during smoking.
We have previously shown that smokers and
heavy drinkers have increased in vitro
production of acetaldehyde in saliva
(Homann et al., 2000; Salaspuro, 2003).
Here, we have further demonstrated that
tobacco smoking dramatically increases
salivary acetaldehyde concentration in vivo.
These findings support our hypothesis on
the carcinogenic role of local acetaldehyde
in the upper digestive tract. Systemic
acetaldehyde levels are negligible during
both drinking and smoking.
All acetaldehyde was eliminated from the
oral cavity during smoking with a rather
small dose of L-cysteine (5 mg). As
mentioned in the literature review, cysteine
as a thiol compound forms a stable
thiazolidine carboxylic acid (MTCA) when
reacting with acetaldehyde. MTCA has also
been shown to be endogenously formed in
the human body when L-cysteine inactivates
endogenous or exogenous acetaldehyde.
Despite our limited understanding of
MTCA, evidence indicates that MTCA
undergoes endogenous nitrosation, forming
nitrosothiazolidine 4-carboxylic acid
(NMTCA) (Ohshima and Bartsch, 1984).
This substance has been detected in the
urine of human volunteers without
exogenous administration of the precursors.
Cigarette smokers have also been shown to
excrete higher levels of NMTCA than non-
smokers. The NMTCA has been suggested
to develop when acetaldehyde from cigarette
smoke reacts with endogenous L-cysteine
(Ohshima and Bartsch, 1984). The L-
cysteine lozenge offers a supplemental
chemopreventive agent that binds
acetaldehyde before it interacts with
endogenous detoxification mechanisms.
The results of this thesis strongly suggest
that a cysteine tablet sucked during every
smoking episode could serve as a
chemopreventive, acetaldehyde-eliminating
agent. Moreover, its use can be considered
safe; no reports have been made of harmful
effects of L-cysteine (at the concentrations
described here) or cysteine-acetaldehyde
metabolites. However, even with the
elimination of acetaldehyde, other important
carcinogens remain in tobacco smoke.
Smoking should therefore be avoided.
Nevertheless, as approximately 43-63% of
upper gastrointestinal tract cancers are
attributable to tobacco smoking, even a
small reduction in the carcinogenicity of
cigarette smoke would provide considerable
benefits. Further elucidation of the effects of
the cysteine tablet on cancer prevention




The main conclusions of this thesis are:
1. In vitro results with E. coli demonstrate
that individual bacteria representing the
normal microbiota of the human
gastrointestinal tract can be a contributing
factor in the previously described microbial
pathway for ethanol metabolism. Aerobic
and, more importantly, microaerobic
conditions prevailing on the mucosal surface
of the gut enable ADH-mediated ethanol
oxidation. This may also lead to marked
formation of carcinogenic acetaldehyde
from ethanol in vivo. Furthermore, toxic
acetaldehyde may be produced by bacteria
without exogenously provided ethanol
during anaerobic fermentation. This may
contribute to the individual levels of
endogenous acetaldehyde.
2. Smokers, as compared with non-smokers,
have significantly increased acetaldehyde
exposure during ethanol metabolism, even
when not smoking. This most probably is
due to changes in the oral microbiota of
chronic smokers. Moreover, acetaldehyde
exposure is dramatically increased during
active tobacco smoking due to the
significant deposition of smoke-derived
acetaldehyde into saliva. Thus, the increased
aerodigestive tract cancer risk observed in
smokers may be the result of the
acetaldehyde exposure from tobacco smoke.
Furthermore, the markedly increased
exposure to carcinogenic acetaldehyde
caused by simultaneous smoking and
drinking may explain the synergistic and
multiplicative effect of alcohol consumption
and smoking on upper digestive tract
carcinogenesis.
3. Acetaldehyde produced in the oral cavity
by microbial ethanol oxidation could be
significantly decreased by a new buccal L-
cysteine-releasing drug formulation. L-
cysteine efficiently binds reactive
acetaldehyde by forming a stable
thiazolidine compound, thus preventing
acetaldehyde from interacting with cellular
proteins and DNA. As two-thirds of
acetaldehyde can be trapped in saliva, our
finding presents a means of decreasing the
acetaldehyde exposure of individuals who
have a greater cancer risk due to increased
acetaldehyde concentration in saliva, such as
ALDH2-deficient Asians, Caucasians with
high activity ADH, smokers and heavy
drinkers. Thus, buccal cysteine tablets could
potentially be used to prevent upper
digestive tract cancers induced by ethanol-
derived acetaldehyde.
4. Study IV corroborates previous results
that acetaldehyde − the major volatile
substance of tobacco smoke is dissolved in
saliva during smoking. This acetaldehyde
can be completely removed by a L-cysteine
lozenge. Hence, cysteine tablet sucked
during every smoking period could be used
to minimize acetaldehyde exposure, thus
potentially preventing upper digestive tract
cancers in smokers. However, it should be
born in mind that smoking remains harmful
because cysteine is not likely to inactivate
all carcinogens present in tobacco smoke.
In conclusion, undisputed evidence reveals
that alcohol consumption and tobacco
smoking are the main risk factors for upper
digestive tract cancers in humans. Strong
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experimental and human genetic linkage
data also indicate that acetaldehyde is one of
the main contributors to the carcinogenic
effect. This thesis confirms the earlier
findings and further elucidates the role of
acetaldehyde in the pathogenesis of alcohol-
and smoking-induced cancers. We also
present a novel experimental approach to
decreasing local acetaldehyde exposure of
the upper digestive tract with L-cysteine,
with the eventual goal of reducing the
prevalence of upper digestive tract cancers.
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